var title_f28_31_29168="TB tracheal stenosis CT";
var content_f28_31_29168=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe tracheal stenosis caused by tuberculosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 224px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomographic scan shows critical narrowing of the lower trachea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_31_29168=[""].join("\n");
var outline_f28_31_29168=null;
var title_f28_31_29169="KS involvement of colon";
var content_f28_31_29169=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kaposi's sarcoma of the colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaposi's sarcoma of the gastrointestinal tract in a patient with AIDS presenting as large annular masses with circumferential infiltration and luminal obstruction in the colon and rectum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     By permission from: van den Brink MR, Dezube BJ, J Clin Oncol 1997; 15:1283.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_31_29169=[""].join("\n");
var outline_f28_31_29169=null;
var title_f28_31_29170="Tender points in fibromyalgia";
var content_f28_31_29170=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F77950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F77950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Tender points in fibromyalgia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 18 \"tender points\" important for the diagnosis of fibromyalgia. Note the bilateral symmetry of the labeled regions. Tenderness on palpation of at least 11 of these sites in a patient with at least a three month history of diffuse musculoskeletal pain is recommended as a diagnostic standard for fibromyalgia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Goldenberg, DL, Hosp Pract (Off Ed) 1989; 24:39.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_31_29170=[""].join("\n");
var outline_f28_31_29170=null;
var title_f28_31_29171="Left atrial myxoma five chamber echocardiogram 2";
var content_f28_31_29171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/71550/5chlamy2_conv.mp4?title=Left+atrial+myxoma+five+chamber+echocardiogram+2\" style=\"width:312px;height:224px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left atrial myxoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 236px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The five chamber view from a 2-D echocardiogram shows a very large atrial myxoma which adherent to the interatrial septum by a broad stalk and extends into the left ventricle during diastole.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_31_29171=[""].join("\n");
var outline_f28_31_29171=null;
var title_f28_31_29172="Cefaclor: Patient drug information";
var content_f28_31_29172=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cefaclor: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/11/27829?source=see_link\">",
"     see \"Cefaclor: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/22/12644?source=see_link\">",
"     see \"Cefaclor: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F146901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cefaclor&reg;;",
"     </li>",
"     <li>",
"      Ceclor&reg;;",
"     </li>",
"     <li>",
"      Novo-Cefaclor;",
"     </li>",
"     <li>",
"      Nu-Cefaclor;",
"     </li>",
"     <li>",
"      PMS-Cefaclor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701734",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cefaclor or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695751",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take capsule, chewable tablet, or liquid with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695776",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take long-acting products with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chewable tablet: Chew or crush well. Mix crushed tablet with food. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699479",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) in a refrigerator. Throw away any part not used after 2 weeks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11808 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C264CC6E5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_31_29172=[""].join("\n");
var outline_f28_31_29172=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146901\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015495\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015494\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015499\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015500\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015502\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015497\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015498\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015503\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015504\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/11/27829?source=related_link\">",
"      Cefaclor: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/22/12644?source=related_link\">",
"      Cefaclor: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_31_29173="Lapatinib: Patient drug information";
var content_f28_31_29173=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lapatinib: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     see \"Lapatinib: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4424626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tykerb&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8103386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tykerb&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700734",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems. Call your doctor if you see dark urine, feel tired, are not hungry, have an upset stomach, are throwing up, or have yellowing of the skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691765",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat breast cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702361",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lapatinib or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698126",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the heart may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698227",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the lungs may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705874",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take once a day. Do not split up the dose during the day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11796 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-C2273CD5CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_31_29173=[""].join("\n");
var outline_f28_31_29173=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424626\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8103386\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028691\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028693\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028692\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028697\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028698\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028700\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028695\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028696\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028701\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028702\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=related_link\">",
"      Lapatinib: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_31_29174="Hemodialysis in the elderly patient";
var content_f28_31_29174=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hemodialysis in the elderly patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/31/29174/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/31/29174/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/31/29174/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/31/29174/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/31/29174/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/31/29174/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/31/29174/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the primary treatment of elderly end stage renal disease (ESRD) patients (greater than 75 years of age) is in-center hemodialysis (96 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/1\">",
"     1",
"    </a>",
"    ]. Continuous ambulatory peritoneal dialysis or continuous cycler peritoneal dialysis",
"    <span class=\"nowrap\">",
"     (CAPD/CCPD)",
"    </span>",
"    account for approximately 3.5 percent, while only 0.3 percent are treated with home hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The average age of the patient undergoing dialysis in the United States has been steadily increasingly over the last several decades. In 2000, for example, the average age was approximately 62 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number of elderly initiating dialysis is also increasing. In a survey using the United States Renal Data System database, the number of patients 80 years of age and older who initiated dialysis increased from 7054 patients in 1996 to 13,577 individuals in 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/3\">",
"     3",
"    </a>",
"    ]. After adjustment for population growth, the rate of dialysis initiation had increased by 57 percent over this time period. However elderly patients may be less likely to be started on dialysis compared with younger patients with a similar degree of kidney dysfunction. This was suggested by a community based cohort study of over 1.8 million adults in Alberta, Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/4\">",
"     4",
"    </a>",
"    ]. At a follow-up of 4.4 years, among patients who had an estimated GFR of 15 to 29",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    at the beginning of the study, the rate of untreated kidney failure (defined as estimated GFR &lt;15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ) was over fivefold greater for patients older than 85 years of age compared with those 18 to 44 years. The individual reasons for withholding dialysis cannot be determined from this study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Important points to consider when evaluating the treatment of elderly patients with ESRD include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The life expectancy of such patients",
"     </li>",
"     <li>",
"      The effect of ESRD on life expectancy and quality of life",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data from the United States Renal Data System (USRDS) indicate that patients aged 65 or more undergoing dialysis have a life-expectancy of approximately four years, which is markedly lower than that of a patient of the same age without ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/6\">",
"     6",
"    </a>",
"    ]. Additionally, in one Canadian study of patients older than 75 years of age, survival at one, three, and five years was 69, 37, and 20 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], although survival has improved over the last decade [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/8\">",
"     8",
"    </a>",
"    ]. The impact of ESRD on life expectancy generally decreases with increasing age, and is small for the oldest age groups.",
"   </p>",
"   <p>",
"    Despite limited survival for some patients, many elderly patients have a high quality of life on dialysis, lending support to the policy of the continued offering of ESRD therapy to these patients. In addition, most elderly patients would choose dialysis therapy if given the therapeutic option, particularly if symptoms were relieved and independence was maintained [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/9\">",
"     9",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    However, dialysis in the elderly remains a challenge and raises ethical and socioeconomic concerns. It is reasonable to question, for example, whether it is proper to offer expensive and complicated treatment to a growing worldwide population of older patients with renal failure who have a limited life expectancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major hemodialysis concerns in elderly subjects are discussed in this topic review. Complications of hemodialysis in these patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14101?source=see_link\">",
"     \"Complications of hemodialysis in the elderly patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OUTCOMES OF HEMODIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite complex comorbid and psychosocial conditions, survival and the quality of life in the elderly patient on hemodialysis is frequently acceptable. Multiple studies have drawn variable conclusions based upon the period of evaluation, type of patient, study design, and outcome measured. As examples [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/11-26\">",
"     11-26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Observational studies have found significantly improved survival in elderly patients who initiated dialysis versus those treated conservatively [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/24,26\">",
"       24,26",
"      </a>",
"      ]. As an example, an observational single center study of 202 elderly patients with ESRD found higher median survival among those who underwent dialysis versus patients treated conservatively (38 versus 14 months, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An acceptable subjective quality of life and degree of rehabilitation have also been noted in many other reports [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/12-21\">",
"       12-21",
"      </a>",
"      ]. It has been proposed that the regular visit to the dialysis unit and mixing with younger patients may act as a beneficial social stimulus in elderly subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other studies have painted a much grimmer picture of the life of elderly dialysis patients, with the initiation of dialysis being associated with high mortality and a sustained decline in functional status [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/22,23,25\">",
"       22,23,25",
"      </a>",
"      ]. One study of 3701 nursing home residents who initiated dialysis found that, one year after dialysis was begun, nearly 60 percent had died and only 13 percent had maintained their predialysis functional status [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/25\">",
"       25",
"      </a>",
"      ]. Thus, frail elderly nursing home residents perform relatively poorly with maintenance dialysis, particularly if effective rehabilitation is not performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Outcomes among the very old",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have examined survival among the over old [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/3,27,28\">",
"     3,27,28",
"    </a>",
"    ]. In one study from the United States Renal Data System, the one-year mortality of patients aged 80 and older was 46 percent, which had not changed in the period from 1996 to 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Independent predictors of poor survival among the very old include older age, poor nutritional status, nonambulatory status, late referral for dialysis initiation, and the presence of significant comorbid conditions, particularly cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/3,29\">",
"     3,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the aggregate, prolonged survival is feasible in elderly hemodialysis patients. This is particularly true among relatively robust elderly patients. Dialysis should therefore not be denied to elderly patients, even the very old, if there is hope for prolongation of an enjoyable span of life. However, dialysis should not be used merely to prolong the dying process.",
"   </p>",
"   <p>",
"    Furthermore, the observation that a significant proportion of these patients can be successfully managed by home hemodialysis illustrates the ability of elderly subjects to adapt to a complicated treatment regimen. As in younger patients, survival is higher with home versus in-center dialysis; however, selection bias may have contributed to this difference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PERMANENT VASCULAR ACCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endogenous arteriovenous (AV) fistulas, polytetrafluoroethylene (PTFE) grafts and surgically implanted percutaneous permcaths are all used in elderly patients for permanent vascular access. If the patient does not have severe peripheral vascular disease, the initial attempt at vascular access surgery should be a AV fistula due its lower incidence of infectious complications.",
"   </p>",
"   <p>",
"    AV fistula can be successful even in the very old, although conflicting results have been reported. Some reports suggest a success rate of 82 to 87 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Others, however, have not been able to reproduce these results, finding a success rate of only a 25 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. By comparison, some studies have reported no differences in survival in older and younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another problem is that many elderly people do not have suitable vessels for successful creation of an endogenous AV fistula; this is particularly true in patients with diabetes and hypertensive vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/33,35\">",
"     33,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, 1- and 2-year PTFE patency rates of 75 to 80 percent and 70 percent, respectively, are achieved in elderly patients, which is not markedly different from those achieved in patients less than 65 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/32,33,35-38\">",
"     32,33,35-38",
"    </a>",
"    ]. Infection and pseudoaneurysm formation also may occur with the same frequency in both age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although age may reduce the likelihood of successful autologous AV fistula maturation, every opportunity for its construction should be taken. Data from the United States Renal Data Survey (USRDS) indicate that the risk of access failure in patients over age 65 with an AV fistula is 24 percent lower than in similar patients having a PTFE graft [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    Vascular Access Guidelines recommend that greater than 65 percent of prevalent patients should have native AV fistulae constructed. Since the median age of new patients starting hemodialysis exceeds 60 years, this target is not achievable unless the elderly have more native accesses constructed.",
"   </p>",
"   <p>",
"    Placement of cuffed silicone rubber permcath in the internal or external jugular veins can be considered in elderly patients with extensive peripheral vascular disease, exhausted access sites, short life expectancy from other comorbidities, or chronic hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/7\">",
"     7",
"    </a>",
"    ]. The last is associated with poor maintenance of access patency and the need for many salvage procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ADEQUACY OF DIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have clearly documented the relationship between the dose of dialysis and mortality, and preliminary data in the United States have demonstrated improved survival with increasing dialysis (as estimated from the",
"    <span class=\"nowrap\">",
"     Kt/V).",
"    </span>",
"   </p>",
"   <p>",
"    Several",
"    problems can contribute to decreased dialysis delivery in the elderly.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perhaps the most important is decreased protein intake and muscle mass, resulting in low blood urea nitrogen and plasma creatinine concentrations.",
"     </li>",
"     <li>",
"      Elderly patients experience more intradialytic complications, such as hypotension, nausea, and vomiting, than younger patients. The treatment of hypotension is often associated with temporary cessation or early termination of hemodialysis therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PERITONEAL DIALYSIS VERSUS HEMODIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several problems that interfere with the ability to compare the outcome with peritoneal dialysis and hemodialysis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Due to patient selection, those treated with peritoneal dialysis may differ from those receiving hemodialysis in terms of demographics, comorbid conditions, and social circumstances.",
"     </li>",
"     <li>",
"      An important analytic consideration is how to deal with patients who switch to alternate forms of dialysis, receive a transplant, or are lost to follow-up. In general, two methods are used: an \"intent to treat\" analysis which ignores changes in dialytic therapy and continues follow-up until death or the end of study; or a \"treatment-history\" analysis which censors survival times when the patient changes therapy. In both methods, survival time is censored when a patient receives a transplant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few specific studies have addressed comparative survival with different forms of dialysis in the elderly. One report compared outcomes in 480 patients on CAPD and 373 patients on hemodialysis (all ages) in six Italian centers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/40\">",
"     40",
"    </a>",
"    ]. Differences in demographics and comorbid conditions between the two groups were adjusted using a Cox proportional-hazards-regression analysis. There was no overall difference in mortality between the two modalities. However, mortality was higher among older patients treated with hemodialysis. Another Italian study had similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some series have suggested that the benefit of hemodialysis in the elderly is most prominent in diabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. In one large trial, for example, the relative risk for death was higher among elderly diabetics undergoing peritoneal dialysis than those on hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, several studies have found no difference in survival between PD and hemodialysis among the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/45,46\">",
"     45,46",
"    </a>",
"    ], including diabetics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/45\">",
"     45",
"    </a>",
"    ]. Possible reasons for these different observations include inconsistent adjustment for comorbid conditions, different follow-up periods and variations in populations studied.",
"   </p>",
"   <p>",
"    In general, the risk of death with modality varies with age, with peritoneal dialysis having a relatively increased mortality in older patients. However, it appears that the variable results are due to differences among incident patients and the type of analytical method utilized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34312?source=see_link\">",
"     \"Dialysis modality and patient outcome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Technique failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcomes of CAPD compared to hemodialysis in elderly patients is also heavily influenced by the number of patients who are unable to continue with one or the other modality. Data obtained from the USRDS have shown the following [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among elderly subjects (age &gt;65 years) who started on hemodialysis 1.7 percent switched to",
"      <span class=\"nowrap\">",
"       CAPD/CCPD",
"      </span>",
"      within the subsequent 12 months; the corresponding value for patients who started on",
"      <span class=\"nowrap\">",
"       CAPD/CCPD",
"      </span>",
"      and switched to hemodialysis at one year was 12.5 percent.",
"     </li>",
"     <li>",
"      The fraction of patients who remained on the same modality at one year was 63 percent with hemodialysis versus 49 percent with",
"      <span class=\"nowrap\">",
"       CAPD/CCPD.",
"      </span>",
"      The remaining patients died, were transplanted, or switched to another modality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This analysis does not include modality data before 90 days of therapy, a time when switching dialysis modalities is relatively common. If technique survival is analyzed from day one of renal replacement therapy, data from the Canadian registry revealed a rapid decline in survival with hemodialysis within the first six months which then began to level off [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/48\">",
"     48",
"    </a>",
"    ]. In comparison, a more gradual but continuing decline was observed in patients treated with the peritoneal dialysis group. At approximately one year, where the curves intersected, technique survival was approximately 80 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with younger patients, older individuals are more likely to initiate renal replacement therapy with hemodialysis. In one single center study, for example, patients older than 75 years of age were more frequently treated by hemodialysis than peritoneal dialysis (81 versus 19 percent) when compared to their younger counterparts (65 versus 35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29174/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite limited survival for some patients, many elderly patients have a high quality of life on dialysis, lending support to the policy of the continued offering of ESRD therapy to these patients. Most elderly patients would also choose dialysis therapy if given the therapeutic option, particularly if symptoms were relieved and independence was maintained. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Outcomes of hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dialysis should therefore not be denied to elderly patients, even the very old, if there is hope for prolongation of an enjoyable span of life. However, dialysis should not be used merely to prolong the dying process. When there is doubt about chances of recovery from a severe underlying disease, a \"trial\" of dialysis may be offered. Withdrawal of dialysis at a later time is preferable to withholding it from the beginning. The major contraindications to dialysis are advanced malignancy (with the possible exception of multiple myeloma) or irreversible dementia or advanced liver disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Outcomes of hemodialysis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8072?source=see_link\">",
"       \"Withdrawal from and withholding of dialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Peritoneal dialysis or hemodialysis are the two principal options for renal replacement therapy in most elderly patients. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Choice of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18075210\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Nuhad Ismail, MD, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/1\">",
"      United States Renal Data System. Excerpts from the USRDS 2005 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2006; 47(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/2\">",
"      Hansberry MR, Whittier WL, Krause MW. The elderly patient with chronic kidney disease. Adv Chronic Kidney Dis 2005; 12:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/3\">",
"      Kurella M, Covinsky KE, Collins AJ, Chertow GM. Octogenarians and nonagenarians starting dialysis in the United States. Ann Intern Med 2007; 146:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/4\">",
"      Hemmelgarn BR, James MT, Manns BJ, et al. Rates of treated and untreated kidney failure in older vs younger adults. JAMA 2012; 307:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/5\">",
"      Kurella Tamura M, Winkelmayer WC. Treated and untreated kidney failure in older adults: what's the right balance? JAMA 2012; 307:2545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/6\">",
"      United States Renal Data System. Excerpts from the USRDS 2009 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2010; 55(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/7\">",
"      L&eacute;tourneau I, Ouimet D, Dumont M, et al. Renal replacement in end-stage renal disease patients over 75 years old. Am J Nephrol 2003; 23:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/8\">",
"      Jassal SV, Trpeski L, Zhu N, et al. Changes in survival among elderly patients initiating dialysis from 1990 to 1999. CMAJ 2007; 177:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/9\">",
"      Ahmed S, Addicott C, Qureshi M, et al. Opinions of elderly people on treatment for end-stage renal disease. Gerontology 1999; 45:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/10\">",
"      Mignon F, Michel C, Mentre F, Viron B. Worldwide demographics and future trends of the management of renal failure in the elderly. Kidney Int Suppl 1993; 41:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/11\">",
"      Westlie L, Umen A, Nestrud S, Kjellstrand CM. Mortality, morbidity, and life satisfaction in the very old dialysis patient. Trans Am Soc Artif Intern Organs 1984; 30:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/12\">",
"      Tapson JS, Rodger RS, Mansy H, et al. Renal replacement therapy in patients aged over 60 years. Postgrad Med J 1987; 63:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/13\">",
"      Schaefer K, Asmus G, Quellhorst E, et al. Optimum dialysis treatment for patients over 60 years with primary renal disease. Survival data and clinical results from 242 patients treated either by haemodialysis or haemofiltration. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985; 21:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/14\">",
"      Williams AJ, Antao AJ. Referral of elderly patients with end-stage renal failure for renal replacement therapy. Q J Med 1989; 72:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/15\">",
"      Park, MS, Lee, HB. Outcome of dialysis in the elderly. Geriatr Nephrol Urol 1992; 1:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/16\">",
"      Panarello G, De Baz H, Cecchin E, Tesio F. Dialysis for the elderly: survival and risk factors. Adv Perit Dial 1989; 5:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/17\">",
"      Ismail N, Hakim RM, Oreopoulos DG, Patrikarea A. Renal replacement therapies in the elderly: Part 1. Hemodialysis and chronic peritoneal dialysis. Am J Kidney Dis 1993; 22:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/18\">",
"      Triolo G, Segoloni GP, Salomone M, et al. Comparison between two dialytic populations undergoing renal transplantation. Adv Perit Dial 1990; 6:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/19\">",
"      Wall, J. Dialysis in the elderly. Some UK experience. Adv Perit Dial 1990; 6:82.",
"     </a>",
"    </li>",
"    <li>",
"     Battelle Human Affairs Research Centers. National Kidney Dialysis and Kidney Transplantation Study, Seattle, WA, 1985.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/21\">",
"      Evans RW, Manninen DL, Garrison LP Jr, et al. The quality of life of patients with end-stage renal disease. N Engl J Med 1985; 312:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/22\">",
"      Ifudu O, Mayers J, Matthew J, et al. Dismal rehabilitation in geriatric inner-city hemodialysis patients. JAMA 1994; 271:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/23\">",
"      Byrne C, Vernon P, Cohen JJ. Effect of age and diagnosis on survival of older patients beginning chronic dialysis. JAMA 1994; 271:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/24\">",
"      Murtagh FE, Marsh JE, Donohoe P, et al. Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. Nephrol Dial Transplant 2007; 22:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/25\">",
"      Kurella Tamura M, Covinsky KE, Chertow GM, et al. Functional status of elderly adults before and after initiation of dialysis. N Engl J Med 2009; 361:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/26\">",
"      Carson RC, Juszczak M, Davenport A, Burns A. Is maximum conservative management an equivalent treatment option to dialysis for elderly patients with significant comorbid disease? Clin J Am Soc Nephrol 2009; 4:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/27\">",
"      R&ouml;hrich B, Asmus G, von Herrath D, Schaefer K. Is it worth performing kidney replacement therapy on patients Over 80? Nephrol Dial Transplant 1996; 11:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/28\">",
"      Peri UN, Fenves AZ, Middleton JP. Improving survival of octogenarian patients selected for haemodialysis. Nephrol Dial Transplant 2001; 16:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/29\">",
"      Joly D, Anglicheau D, Alberti C, et al. Octogenarians reaching end-stage renal disease: cohort study of decision-making and clinical outcomes. J Am Soc Nephrol 2003; 14:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/30\">",
"      Pourchez, T, Moriniere, P, St Priest, A. Outcome of vascular access for hemodialysis in the elderly (&gt;75 years) (abstract). Proc Eur Dial Transplant Assoc 1990; 27:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/31\">",
"      Wing, AJ, Brunner, FP, Brynger, H. Combined report on regular dialysis and transplantation in Europe, IX 1978. Proc Eur Dial Transplant Assoc 1979; 13:2.",
"     </a>",
"    </li>",
"    <li>",
"     Porush, JD, Faubert, PF. Chronic renal failure. In: Renal Disease in the Aged, Porush, J, Faubert (Eds), Little, Brown, Boston, 1991, p. 285.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/33\">",
"      Hinsdale, JG, Lipcouritz, GS, Hoover, EL. Vascular access in the elderly: Results and perspectives in a geriatric population. Dial Transplant 1985; 14:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/34\">",
"      Graspa, EJ, Paraskevopoulos, AP, Moutafis, SP, et al. Complications of vascular access in hemodialysis (HD)-aged versus adult patients. Geriatric Nephrol Urol 1998; 8:21.",
"     </a>",
"    </li>",
"    <li>",
"     Didlake, R, Raju, S, Rhodes, RS, Bower J. Dialysis access in patients older than 65 years. In: Vascular Access for Hemodialysis &mdash; II, Sommer, BG, Henry, ML (Eds), W L Gore and Assoc, Inc, 1991, p. 166.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/36\">",
"      Windus DW, Jendrisak MD, Delmez JA. Prosthetic fistula survival and complications in hemodialysis patients: effects of diabetes and age. Am J Kidney Dis 1992; 19:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/37\">",
"      Palder SB, Kirkman RL, Whittemore AD, et al. Vascular access for hemodialysis. Patency rates and results of revision. Ann Surg 1985; 202:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/38\">",
"      Lok CE, Oliver MJ, Su J, et al. Arteriovenous fistula outcomes in the era of the elderly dialysis population. Kidney Int 2005; 67:2462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/39\">",
"      Woods JD, Turenne MN, Strawderman RL, et al. Vascular access survival among incident hemodialysis patients in the United States. Am J Kidney Dis 1997; 30:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/40\">",
"      Maiorca R, Vonesh EF, Cavalli P, et al. A multicenter, selection-adjusted comparison of patient and technique survivals on CAPD and hemodialysis. Perit Dial Int 1991; 11:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/41\">",
"      Lupo A, Cancarini G, Catizone L, et al. Comparison of survival in CAPD and hemodialysis: a multicenter study. Adv Perit Dial 1992; 8:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/42\">",
"      Nelson, CB, Port, FK, Guire, KE. Dialysis patient survival: Evaluation of CAPD vs hemodialysis using 3 techniques. Perit Dial Int 1992; 12:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/43\">",
"      Bloembergen WE, Port FK, Mauger EA, Wolfe RA. A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1995; 6:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/44\">",
"      Winkelmayer WC, Glynn RJ, Mittleman MA, et al. Comparing mortality of elderly patients on hemodialysis versus peritoneal dialysis: a propensity score approach. J Am Soc Nephrol 2002; 13:2353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/45\">",
"      Jaar BG, Coresh J, Plantinga LC, et al. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 2005; 143:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29174/abstract/46\">",
"      Foley RN, Parfrey PS, Harnett JD, et al. Mode of dialysis therapy and mortality in end-stage renal disease. J Am Soc Nephrol 1998; 9:267.",
"     </a>",
"    </li>",
"    <li>",
"     Bloembergen, WE, Nelson, CB, Port, FK. Outcomes of CAPD versus hemodialysis in the elderly. In: Nephrology and Urology in the Aged Patient, Oreopoulos, DG, Mchelis, MF, Herschorn, S (Eds), Kluwer Academic Publishers, Amsterdam, 1993, p. 251.",
"    </li>",
"    <li>",
"     Posen, GA, Fenton, SS, Arbus, GS, et al. The Canadian experience with peritoneal dialysis in the elderly. Adv Perit Dial 1990; 6:47.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1870 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-08BE826B45-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_31_29174=[""].join("\n");
var outline_f28_31_29174=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OUTCOMES OF HEMODIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Outcomes among the very old",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PERMANENT VASCULAR ACCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ADEQUACY OF DIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PERITONEAL DIALYSIS VERSUS HEMODIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Technique failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18075210\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14101?source=related_link\">",
"      Complications of hemodialysis in the elderly patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34312?source=related_link\">",
"      Dialysis modality and patient outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8072?source=related_link\">",
"      Withdrawal from and withholding of dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_31_29175="Nonepileptic paroxysmal disorders in children";
var content_f28_31_29175=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonepileptic paroxysmal disorders in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/31/29175/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/31/29175/contributors\">",
"     Thien T Nguyen, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/31/29175/contributors\">",
"     Peter W Kaplan, MB, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/31/29175/contributors\">",
"     Angus Wilfong, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/31/29175/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/31/29175/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/31/29175/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/31/29175/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/31/29175/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 31, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epilepsy is a condition characterized by recurrent seizures. The term seizure refers to a transient occurrence of signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms due to abnormally excessive neuronal activity of the brain. Many pediatric epilepsy centers find that least 20 percent of referrals do not have epileptic seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/1-4\">",
"     1-4",
"    </a>",
"    ] Many of these children are referred for evaluation of spells that are later determined to be temper tantrums, oppositional defiant behavior, and attention deficit",
"    <span class=\"nowrap\">",
"     disorder/attention",
"    </span>",
"    deficit hyperactivity disorder",
"    <span class=\"nowrap\">",
"     (ADD/ADHD).",
"    </span>",
"    Others have stereotyped paroxysmal disorders that may look like seizures and may even have loss of consciousness and unusual motor phenomena. A few children have behavior that initially sounds like true seizures but on video-electroencephalogram (EEG) monitoring proves to be nonepileptic. Nonepileptic paroxysmal events are not uncommon in children and can lead to multiple trials of anticonvulsant medications before the correct diagnosis is recognized.",
"   </p>",
"   <p>",
"    The common nonepileptic disorders that can mimic seizures in children will be reviewed here. A more detailed discussion of the clinical and historical phenomena that help distinguish true seizures from nonepileptic events and the emergent evaluation of children and adolescents with syncope is discussed separately. Nonepileptic paroxysmal events more common in infancy and in adolescents are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21912?source=see_link\">",
"     \"Overview of the classification, etiology, and clinical features of pediatric seizures and epilepsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11432?source=see_link\">",
"     \"Emergent evaluation of syncope in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in infancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MIGRAINE SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent headaches with a family history of migraine rarely present a diagnostic dilemma. However, acute neurologic events without significant headache, particularly those with loss or alteration of consciousness, can be misdiagnosed as seizures. A migraine attack may be dominated by neurologic symptoms, including visual hallucinations, confusion, stupor and coma, total blindness, hemiparesis, or brainstem signs including diplopia, vertigo, and ataxia, so-called basilar-type migraine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=see_link\">",
"     \"Classification of migraine in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44743?source=see_link\">",
"     \"Basilar-type migraine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Post-traumatic migraine is a well-defined syndrome characterized by predominantly neurologic signs occurring after relatively minor head trauma. Some children given the diagnosis of cerebral concussion in reality have suffered an attack of migraine.",
"   </p>",
"   <p>",
"    True epileptic seizures are rarely triggered by a migraine, and it is unusual for a headache to precede an epileptic seizure. More commonly, a migraine-like headache follows a seizure. This latter association is particularly common with generalized tonic-clonic seizures and after partial seizures arising in the occipital regions. Migraine should be suspected if the child has vomiting with the episode, a history of severe headaches without neurologic symptoms exists, or the family has a strong history of headaches [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/5-9\">",
"     5-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Migraine may be associated with epilepsy in children. A population-based case control study found an association between incident epilepsy and migraine with aura (OR=8.1, 95 percent CI, 2.7-24.3) but not migraine without aura [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BENIGN PAROXYSMAL VERTIGO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign paroxysmal vertigo (BPV) is a disorder of early childhood manifested by recurrent episodes of brief disequilibrium [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/11\">",
"     11",
"    </a>",
"    ]. During the attacks, the child appears frightened and off balance, often reaching out to steady himself. The events may be associated with nystagmus, diaphoresis, nausea, and vomiting. Older children will grab nearby persons or furniture for support to prevent falling and may complain of vertigo or dizziness. Episodes usually last less than a minute and are not associated with an altered consciousness. They usually recur in clusters, occurring daily for several days in a row, then remitting for several weeks, and recurring again.",
"   </p>",
"   <p>",
"    The disorder is benign and typically resolves without treatment, usually by five years of age, sometimes longer. Many patients will subsequently develop typical migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/12\">",
"     12",
"    </a>",
"    ]. A family history of migraine is also often noted [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/10\">",
"     10",
"    </a>",
"    ]. Some investigators report abnormal vestibular function tests such as caloric responses, which suggest a peripheral labyrinthine origin for the vertigo, but this has not been a uniform finding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/11\">",
"     11",
"    </a>",
"    ]. The pathophysiology of BPV is unknown.",
"   </p>",
"   <p>",
"    There are no laboratory tests that have been useful in establishing the diagnosis of BPV. One group of investigators noted an increase in creatine kinase-MB in patients with BPV [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/13\">",
"     13",
"    </a>",
"    ]. The significance of this finding and its usefulness in distinguishing BPV from seizures are unclear.",
"   </p>",
"   <p>",
"    BPV remains a diagnosis of exclusion. The main role of the clinician is to differentiate these episodes from seizures, particularly in young children who cannot describe the attacks and whose level of consciousness can be difficult to determine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=see_link&amp;anchor=H13#H13\">",
"     \"Classification of migraine in children\", section on 'Benign paroxysmal vertigo of childhood'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NONEPILEPTIC STARING SPELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staring spells or pseudoabsences occur in children with mental retardation, attention deficit hyperactivity disorder (ADHD), autism, and in some normal children [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/2\">",
"     2",
"    </a>",
"    ]. In one series, these nonepileptic staring spells made up one-third of nonepileptic events in children referred for video-EEG monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pseudoabsences must be distinguished from true absence seizures, particularly in the child with ADHD and staring spells. Nonepileptic staring spells usually occur when the child is either bored or inactive, such as when watching TV or sitting in a classroom [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/4\">",
"     4",
"    </a>",
"    ]. The staring episodes can be interrupted by tactile or vocal stimulation (but usually not hand-waving); rarely occur during physical activity; and are never associated with automatisms, myoclonus, or the other motor signs that typify true absence seizures.",
"   </p>",
"   <p>",
"    Hyperventilation can be a useful tool in the office setting. &nbsp;However, both true and pseudoabsence seizures may be precipitated by hyperventilation. The child is asked to deeply overbreathe for at least three minutes. Younger children can be asked to blow out imaginary candles or blow objects out of the examiner's hand.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An absence seizure is usually obvious; there is a sudden cessation of overbreathing, a stare often with slow upward deviation of the eyes; low-amplitude myoclonic jerks (three per second) of the facial musculature, head, and upper extremities; and in most children, automatisms (eg, chewing, swallowing, lip-smacking, fussing with clothing). The seizure usually lasts a few seconds but can continue for 15 to 20 seconds. The child is amnestic for the absence and cannot recall nonsense words presented by the examiner during the seizure. Occasionally, the child will have increased extensor tone of the trunk characterized by a slow backward lean when sitting on the examining table. The examiner should sit next to the patient in the unlikely event that hyperventilation precipitates a generalized tonic-clonic seizure. A concurrent electroencephalogram (EEG) is abnormal, with bursts of generalized, three hertz spike and wave activity.",
"     </li>",
"     <li>",
"      A small percentage of children may have benign nonepileptic staring spells during hyperventilation that result from altered consciousness caused by the alkalosis and decreased cerebral blood flow [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/14\">",
"       14",
"      </a>",
"      ]. A concurrent EEG will show generalized high-voltage slow activity, the expected EEG changes in the hyperventilating healthy child, but no epileptiform activity. An inexperienced electroencephalographer may confuse this striking slow activity, called a \"build-up,\" with the paroxysmal activity of an absence seizure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Video-EEG monitoring is a useful tool for distinguishing epileptic and nonepileptic staring spells [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/4,15\">",
"     4,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PSYCHOGENIC NONEPILEPTIC SEIZURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychogenic nonepileptic seizures are dramatic behavioral events in a conscious individual that are often misdiagnosed as epileptic seizures and may lead to treatment with antiepileptic drugs. The events typically occur in teenage patients with affective and anxiety disorders and are less common in younger children [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Comorbid epilepsy is common, particularly in children. A family history of seizures or a friend or acquaintance with seizures is a risk factor.",
"   </p>",
"   <p>",
"    Psychogenic nonepileptic seizures often present as a prolonged episode with generalized, atypical-appearing motor activity and a prompt return of consciousness. One study found that younger children (&lt;13 years) were more likely to have more subtle motor manifestations as compared to teenagers and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/16\">",
"     16",
"    </a>",
"    ]. During psychogenic nonepileptic seizures, patients often close their eyes tightly and resist their opening. In contrast, patients having a generalized epileptic convulsion typically have their eyes open.",
"   </p>",
"   <p>",
"    Nonepileptic seizures are best distinguished from true seizures by capture of an event on video-electroencephalogram (EEG) monitoring.",
"   </p>",
"   <p>",
"    Psychogenic nonepileptic seizures are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33226?source=see_link\">",
"     \"Psychogenic nonepileptic seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SYNCOPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope is an abrupt loss of consciousness due to an interruption of energy sources to the brain, usually because of a sudden reduction of cerebral perfusion.",
"   </p>",
"   <p>",
"    In children, most cases of syncope are vasovagal in origin. They are distinguished from seizures by the situation in which they occur (emotional stress, prolonged upright posture, pain) accompanying pallor, prodromal lightheadedness and visual changes, and lack of postictal state. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=see_link&amp;anchor=H2#H2\">",
"     \"Nonepileptic paroxysmal disorders in adolescents and adults\", section on 'Syncope'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rare, but potentially life-threatening cardiac conditions (eg, long QT syndrome) can also present with syncope in children [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/18\">",
"     18",
"    </a>",
"    ]. These events often present without provocation or prodrome, but may mimic a seizure, although pallor is common and postictal confusion is rare. These patients usually have an abnormal cardiac examination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ECG.",
"   </p>",
"   <p>",
"    Breath-holding spells often persist into childhood, but usually present during infancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=see_link&amp;anchor=H8#H8\">",
"     \"Nonepileptic paroxysmal disorders in infancy\", section on 'Breath-holding spells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Syncope in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36007?source=see_link\">",
"     \"Causes of syncope in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11432?source=see_link\">",
"     \"Emergent evaluation of syncope in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MOVEMENT DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkinetic movement disorders or dyskinesias include chorea, dystonia, athetosis, tics, tremors, and ballism. These are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link\">",
"     \"Hyperkinetic movement disorders in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Movement disorders are rarely confused with seizures when the motor activity is classic in appearance and is sustained rather than episodic. Also, impaired consciousness does not occur with movement disorders, and when present, strongly suggests seizures. However, the diagnosis can be confusing when movement disorders present with episodic symptoms and when focal epileptic seizures are characterized by isolated dystonic posturing. Patients with dystonia and other movement disorders may obtain symptomatic relief from sensory tricks, such as lightly touching their face in cervical dystonia. This phenomenon is known as geste antagoniste and may be a useful feature distinguishing these from epilepsy.",
"   </p>",
"   <p>",
"    In children with cognitive impairment, differentiating nonepileptic movements from seizures can be especially challenging. Seizures and nonepileptic motor events often coexist in these patients. In these and other situations, video-EEG monitoring can be extremely helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/4,15\">",
"     4,15",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Tics and stereotypies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tics are relatively brief, sudden, rapid, and intermittent movements (motor tics) or sounds (vocal tics). They may be repetitive and stereotypic. Tics are usually abrupt in onset and brief (clonic tics) but may be slow and sustained (dystonic tics). Tics are associated with a premonitory feeling that is relieved by performing the tics. In contrast to other hyperkinetic dyskinesias or epileptic seizures, children with tics are distractible, and the tics may be temporarily suppressed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/4\">",
"     4",
"    </a>",
"    ]. Tics also differ from epilepsy by the variability of the movement and the urge to perform tics. The myoclonic jerks of juvenile myoclonic epilepsy can be mistaken for tics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/19\">",
"     19",
"    </a>",
"    ]. Tics can occur in Tourette's syndrome but may also be an isolated phenomenon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15849?source=see_link&amp;anchor=H88577538#H88577538\">",
"     \"Juvenile myoclonic epilepsy\", section on 'Clinical Features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22664?source=see_link\">",
"     \"Tourette syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stereotypies are repetitive, purposeless actions such as head banging, head rolling, body rocking, and hand flapping. Similar to tics, stereotypies also may be consciously suppressed and decreased by distraction. Unlike tics, stereotypies are not preceded by a progressive urge or relief following the activities. Often, they manifest as self-stimulating behaviors in response to tension and anxiety and may comfort the patient.",
"   </p>",
"   <p>",
"    Stereotypies may occur alone or may be secondary to trauma, drugs (eg, chronic amphetamine abuse), or toxic-metabolic insult. These movements can be seen in normal children, but are more common in children with schizophrenia, mental retardation, and autism, and are characteristic of Rett syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link\">",
"     \"Hyperkinetic movement disorders in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32218?source=see_link\">",
"     \"Rett syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Paroxysmal dyskinesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;These paroxysmal movement disorders are classified according to the setting in which they occur and can include a variety of movements including dystonia, ballism, and chorea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. These disorders can present in childhood, adolescence, or early adulthood. These are briefly described below and are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link&amp;anchor=H13#H13\">",
"     \"Hyperkinetic movement disorders in children\", section on 'Other causes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=see_link&amp;anchor=H20#H20\">",
"     \"Nonepileptic paroxysmal disorders in adolescents and adults\", section on 'Paroxysmal dyskinesia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paroxysmal hypnogenic dyskinesia consists of dystonic or dyskinetic episodes during or immediately after arousal from non-REM sleep or, more rarely, during wakefulness. These may, in fact be epileptic in origin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=see_link&amp;anchor=H13#H13\">",
"       \"Nonepileptic paroxysmal disorders in adolescents and adults\", section on 'Nocturnal paroxysmal dystonia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Paroxysmal kinesigenic dyskinesia (PKD) consists of brief (less than one minute) attacks of choreoathetosis, dystonia, or both that are precipitated by sudden changes in movement [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. Movements may be unilateral or bilateral. Consciousness is retained. Many individuals have a brief, nonspecific warning or aura prior to an attack. The interictal examination is normal. PKD may be a familial,",
"      <span class=\"nowrap\">",
"       sporadic/idiopathic,",
"      </span>",
"      or secondary condition (due to multiple sclerosis, stroke, traumatic brain injury), and is more common in boys than girls.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"       Carbamazepine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"       phenytoin",
"      </a>",
"      is often highly effective [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Paroxysmal nonkinesigenic dyskinesia consists of attacks of spontaneous, severe dystonia that may be precipitated by alcohol, caffeine, and stress [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/20,23\">",
"       20,23",
"      </a>",
"      ]. The duration of these episodes may be two minutes or several hours, occasionally a day or two. Antiepileptic medications may be efficacious, but less consistently than with PKD. Familial, sporadic, and secondary forms have been described.",
"     </li>",
"     <li>",
"      Paroxysmal exercise-induced dyskinesia consists of brief episodes of dystonia that occur after several minutes of exercise, not at initiation of movement, as in kinesigenic dyskinesia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/20,23\">",
"       20,23",
"      </a>",
"      ]. Typically, the part of the body that has been doing the most exercise becomes dystonic. The abnormal movement resolves gradually with cessation of the exercise. This may be sporadic or a hereditary condition. Antiepileptic drugs are not generally helpful.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/57/28566?source=see_link\">",
"       Acetazolamide",
"      </a>",
"      has been effective in some individuals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SLEEP DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episodes arising out of sleep disturbances are a common cause of nonepileptic events in children referred for video-EEG monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Rhythmic movement disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhythmic movements such as nocturnal head banging, body rocking, and head rolling typically occur in children younger than one year of age as they try to fall asleep, but can first appear at any age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. They also can be present in deep sleep and in wakefulness. They are somewhat more common in children with learning disabilities, but occur in developmentally normal children as well. They can remit within a few years of onset or persist into adulthood. The characteristic nature of the movements is not typical for epilepsy, and patients can often be directed to stop the movements, which is not true for an epileptic seizure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28473?source=see_link&amp;anchor=H17023639#H17023639\">",
"     \"Sleepwalking and other parasomnias in children\", section on 'Rhythmic movement disorder'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sleep walking, night terrors, and confusional arousals",
"    </span>",
"    &nbsp;&mdash;&nbsp;These non-REM sleep arousal disorders are common, occurring in 15 to 20 percent of preadolescent children [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/26\">",
"     26",
"    </a>",
"    ]. The diagnosis and treatment of these disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28473?source=see_link&amp;anchor=H27172788#H27172788\">",
"     \"Sleepwalking and other parasomnias in children\", section on 'Disorders of arousal from non-rapid eye movement (NREM) sleep'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleep walking or somnambulism occurs in up to 15 percent of children between the ages of 5 and 12 years with a peak prevalence between four and six years [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/27\">",
"       27",
"      </a>",
"      ]. While eyes are often open, patients demonstrate a low level of awareness with a blank facial expression and reduced responsiveness to stimulation. Movements are usually slow, clumsy, and purposeless; but more complex and directed activity, as well as agitated behaviors, are also described.",
"      <br/>",
"      <br/>",
"      Postictal wandering after a night-time seizure may be difficult to differentiate from sleep walking. Such patients are usually confused and disoriented, not just less responsive as with sleep walking. Signs indicating a prior seizure might include incontinence or a bitten tongue.",
"     </li>",
"     <li>",
"      Sleep terrors are characterized by a sudden, often dramatic arousal with facial expression, vocalization, and other behaviors that express agitation and fear [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/28\">",
"       28",
"      </a>",
"      ]. Tachycardia, diaphoresis, mydriasis, and other autonomic features are prominent. Patients are difficult to arouse and will fall back to sleep spontaneously after a few to several minutes. These episodes can first manifest at a young age, around 18 months, have a peak prevalence at age five to seven years, and typically resolve prior to adolescence. Triggers include acute stress and sleep deprivation, as well as certain medications including stimulants, neuroleptics, sedatives, and antihistamines.",
"     </li>",
"     <li>",
"      Confusional arousals are characterized by sudden arousal with disorientation, confusion, agitation, and some semipurposeful motor activity. Vocalization with coherent speech is common, but autonomic activation typical of a night terror is not. Episodes last a few to several minutes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These disorders overlap and include as a common feature, a typical duration of a few to 30 minutes. Episodes arise out of sleep stages 3 and 4, typically within the first half of sleep, but after the first 30 to 90 minutes. In an intermediate stage between waking and sleep, patients may respond to stimuli, but not normally. Amnesia is common, but some children report brief dream-like images. It is common for an individual and a family to manifest more than one of these disturbances.",
"   </p>",
"   <p>",
"    These episodes can usually be distinguished from nocturnal seizures, which are usually briefer (a few minutes or less), stereotyped, and more frequent, often occurring in clusters [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/26,28\">",
"     26,28",
"    </a>",
"    ]. In contrast, it is rare for these sleep disturbances to recur in the same night and their average frequency is one to three times a month. Case reports of night terrors that were determined to be epileptic in origin were atypical for sleep terrors because of their short duration, frequency, and occurrence in the second rather than first half of sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Recording episodes on video-EEG and polysomnography is necessary when the diagnosis is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Sleep starts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep starts or hypnic myoclonus refers to a sudden jerking movement upon falling asleep, often accompanied by a subjective sensation of falling [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29175/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. These can occur at almost any age and are usually easily recognized. Rarely, hypnic myoclonus can become unusually violent, very frequent, or repetitive and confused for myoclonic seizures or even tonic-clonic seizures. The myoclonic jerks are restricted to sleep, usually in the transition between sleep and wakefulness, and are not associated with other clinical phenomena. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4711?source=see_link\">",
"     \"Nocturnal leg cramps\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MIGRAINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both migraine and epilepsy are characterized by episodes of neurologic dysfunction that are accompanied by headache, as well as gastrointestinal, autonomic, and psychological features. The differentiation of migraine and seizures episodes is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=see_link&amp;anchor=H24#H24\">",
"     \"Nonepileptic paroxysmal disorders in adolescents and adults\", section on 'Migraine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic reviews those imitators of epilepsy that are most common in children. Disorders more typical of infancy or adolescence can occasionally present in this age group as well (",
"    <a class=\"graphic graphic_table graphicRef81289 \" href=\"UTD.htm?31/38/32364\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in infancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/28/36289?source=see_link\">",
"       \"Patient information: Sleepwalking in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of epileptic seizures in children includes a variety of benign, physiologic phenomena as well as pathologic conditions (",
"    <a class=\"graphic graphic_table graphicRef81289 \" href=\"UTD.htm?31/38/32364\">",
"     table 1",
"    </a>",
"    ). Some of these conditions can persist into childhood and longer.",
"   </p>",
"   <p>",
"    Clinical features of these events help distinguish these from epileptic seizures (see descriptions of individual disorders, above). In difficult cases, electroencephalography (EEG), particularly EEG video monitoring, is useful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=see_link\">",
"     \"Clinical and laboratory diagnosis of seizures in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/1\">",
"      Uldall P, Alving J, Hansen LK, et al. The misdiagnosis of epilepsy in children admitted to a tertiary epilepsy centre with paroxysmal events. Arch Dis Child 2006; 91:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/2\">",
"      Hindley D, Ali A, Robson C. Diagnoses made in a secondary care \"fits, faints, and funny turns\" clinic. Arch Dis Child 2006; 91:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/3\">",
"      Hamiwka LD, Singh N, Niosi J, Wirrell EC. Diagnostic inaccuracy in children referred with \"first seizure\": role for a first seizure clinic. Epilepsia 2007; 48:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/4\">",
"      Bye AM, Kok DJ, Ferenschild FT, Vles JS. Paroxysmal non-epileptic events in children: a retrospective study over a period of 10 years. J Paediatr Child Health 2000; 36:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/5\">",
"      Hockaday JM. Basilar migraine in childhood. Dev Med Child Neurol 1979; 21:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/6\">",
"      Jensen TS. Transient global amnesia in childhood. Dev Med Child Neurol 1980; 22:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/7\">",
"      Sheth RD, Riggs JE, Bodensteiner JB. Acute confusional migraine: variant of transient global amnesia. Pediatr Neurol 1995; 12:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/8\">",
"      Haas DC, Pineda GS, Lourie H. Juvenile head trauma syndromes and their relationship to migraine. Arch Neurol 1975; 32:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/9\">",
"      Golden GS. The Alice in Wonderland syndrome in juvenile migraine. Pediatrics 1979; 63:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/10\">",
"      Ludvigsson P, Hesdorffer D, Olafsson E, et al. Migraine with aura is a risk factor for unprovoked seizures in children. Ann Neurol 2006; 59:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/11\">",
"      Finkelhor BK, Harker LA. Benign paroxysmal vertigo of childhood. Laryngoscope 1987; 97:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/12\">",
"      Drigo P, Carli G, Laverda AM. Benign paroxysmal vertigo of childhood. Brain Dev 2001; 23:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/13\">",
"      R&ouml;d&ouml;&ouml; P, Hellberg D. Creatine kinase MB (CK-MB) in benign paroxysmal vertigo of childhood: a new diagnostic marker. J Pediatr 2005; 146:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/14\">",
"      North KN, Ouvrier RA, Nugent M. Pseudoseizures caused by hyperventilation resembling absence epilepsy. J Child Neurol 1990; 5:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/15\">",
"      Watemberg N, Tziperman B, Dabby R, et al. Adding video recording increases the diagnostic yield of routine electroencephalograms in children with frequent paroxysmal events. Epilepsia 2005; 46:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/16\">",
"      Patel H, Scott E, Dunn D, Garg B. Nonepileptic seizures in children. Epilepsia 2007; 48:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/17\">",
"      Kutluay E, Selwa L, Minecan D, et al. Nonepileptic paroxysmal events in a pediatric population. Epilepsy Behav 2010; 17:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/18\">",
"      MacCormick JM, McAlister H, Crawford J, et al. Misdiagnosis of long QT syndrome as epilepsy at first presentation. Ann Emerg Med 2009; 54:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/19\">",
"      Sethi NK, Labar D, Torgovnick J. Myoclonic epilepsy masquerading as a tic disorder. Clin Neurol Neurosurg 2007; 109:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/20\">",
"      Demirkiran M, Jankovic J. Paroxysmal dyskinesias: clinical features and classification. Ann Neurol 1995; 38:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/21\">",
"      Bruno MK, Hallett M, Gwinn-Hardy K, et al. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology 2004; 63:2280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/22\">",
"      Lotze T, Jankovic J. Paroxysmal kinesigenic dyskinesias. Semin Pediatr Neurol 2003; 10:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/23\">",
"      Bhatia KP. The paroxysmal dyskinesias. J Neurol 1999; 246:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/24\">",
"      Walters AS. Clinical identification of the simple sleep-related movement disorders. Chest 2007; 131:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/25\">",
"      Manni R, Terzaghi M. Rhythmic movements during sleep: a physiological and pathological profile. Neurol Sci 2005; 26 Suppl 3:s181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/26\">",
"      Derry CP, Duncan JS, Berkovic SF. Paroxysmal motor disorders of sleep: the clinical spectrum and differentiation from epilepsy. Epilepsia 2006; 47:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/27\">",
"      Plazzi G, Vetrugno R, Provini F, Montagna P. Sleepwalking and other ambulatory behaviours during sleep. Neurol Sci 2005; 26 Suppl 3:s193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/28\">",
"      Mason TB 2nd, Pack AI. Sleep terrors in childhood. J Pediatr 2005; 147:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/29\">",
"      Huppertz HJ, Franck P, Korinthenberg R, Schulze-Bonhage A. Recurrent attacks of fear and visual hallucinations in a child. J Child Neurol 2002; 17:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29175/abstract/30\">",
"      Lombroso CT. Pavor nocturnus of proven epileptic origin. Epilepsia 2000; 41:1221.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6155 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-BA7A5ED351-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_31_29175=[""].join("\n");
var outline_f28_31_29175=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MIGRAINE SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BENIGN PAROXYSMAL VERTIGO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NONEPILEPTIC STARING SPELLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PSYCHOGENIC NONEPILEPTIC SEIZURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SYNCOPE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MOVEMENT DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Tics and stereotypies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Paroxysmal dyskinesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SLEEP DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Rhythmic movement disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sleep walking, night terrors, and confusional arousals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sleep starts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MIGRAINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6155\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6155|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/38/32364\" title=\"table 1\">",
"      Differential diagnosis of seizures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44743?source=related_link\">",
"      Basilar-type migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36007?source=related_link\">",
"      Causes of syncope in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=related_link\">",
"      Classification of migraine in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=related_link\">",
"      Clinical and laboratory diagnosis of seizures in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11432?source=related_link\">",
"      Emergent evaluation of syncope in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=related_link\">",
"      Hyperkinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15849?source=related_link\">",
"      Juvenile myoclonic epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4711?source=related_link\">",
"      Nocturnal leg cramps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=related_link\">",
"      Nonepileptic paroxysmal disorders in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=related_link\">",
"      Nonepileptic paroxysmal disorders in infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21912?source=related_link\">",
"      Overview of the classification, etiology, and clinical features of pediatric seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/28/36289?source=related_link\">",
"      Patient information: Sleepwalking in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33226?source=related_link\">",
"      Psychogenic nonepileptic seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32218?source=related_link\">",
"      Rett syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28473?source=related_link\">",
"      Sleepwalking and other parasomnias in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22664?source=related_link\">",
"      Tourette syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_31_29176="Invasive liver abscess syndrome caused by Klebsiella pneumoniae";
var content_f28_31_29176=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Invasive liver abscess syndrome caused by Klebsiella pneumoniae",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/31/29176/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/31/29176/contributors\">",
"     Wen-Liang Yu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/31/29176/contributors\">",
"     Yin-Ching Chuang, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/31/29176/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/31/29176/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/31/29176/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/31/29176/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/31/29176/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Klebsiella pneumoniae can produce infection at a variety of sites, with the risk being increased in patients with impaired host defenses (eg, diabetes mellitus, alcoholism, malignancy, chronic obstructive pulmonary disease, and glucocorticoid therapy). K. pneumoniae is also associated with a community-acquired primary invasive liver abscess syndrome. In addition to liver abscess, some patients develop metastatic infection at other sites.",
"   </p>",
"   <p>",
"    Issues related to the K. pneumoniae invasive liver abscess syndrome will be reviewed here. The epidemiology, clinical features (including the general principles of diagnosis and treatment), microbiology, and pathogenesis of K. pneumoniae infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38426?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21801?source=see_link\">",
"     \"Microbiology and pathogenesis of Klebsiella pneumoniae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Klebsiella pneumoniae primary liver abscess has been variably defined in the literature. In one study, for example, primary liver abscess was defined as a K. pneumoniae liver abscess occurring in the absence of predisposing intraabdominal factors, such as hepatobiliary disease, colorectal disease, or a history of intraabdominal surgery or trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/1\">",
"     1",
"    </a>",
"    ]. In other studies, it has been defined by a monomicrobial K. pneumoniae isolate, while polymicrobial liver abscess was usually secondary to hepatobiliary disease or intraabdominal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We prefer to define K. pneumoniae primary liver abscess as liver abscess that occurs in the absence of hepatobiliary disease. Almost all of these infections are monomicrobial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of K. pneumoniae primary liver abscess (KLA), particularly those associated with metastatic infection, have been reported in Taiwan and are community-acquired [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/1-12\">",
"     1-12",
"    </a>",
"    ]. In a series of 248 patients with pyogenic liver abscess from Taiwan, for example, K. pneumoniae was responsible for 171 (69 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Community-acquired KLA has also been described in other countries in Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/7,13-16\">",
"     7,13-16",
"    </a>",
"    ], in Asian patients living in other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/17-23\">",
"     17-23",
"    </a>",
"    ], and in South Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/24\">",
"     24",
"    </a>",
"    ]. It has less commonly been reported in non-Asian patients in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/18,19,25,26\">",
"     18,19,25,26",
"    </a>",
"    ], particularly Hispanics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/18,26\">",
"     18,26",
"    </a>",
"    ], and in Europe and Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. A report from New York, for example, evaluated 79 cases of liver abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/18\">",
"     18",
"    </a>",
"    ]. K. pneumoniae was the most commonly identified pathogen, isolated from 23 of 54 liver abscesses (41 percent) in which an organism was recovered. K. pneumoniae was more commonly isolated among Asian than non-Asian patients (50 versus 27 percent).",
"   </p>",
"   <p>",
"    A minority of patients with KLA, mostly from Taiwan, develops metastatic infection, most commonly manifested as endophthalmitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    meningitis. The incidence of metastatic infection in the setting of KLA is about 12 percent in series from Taiwan and is more common in KLA than in liver abscesses of other bacterial etiology (15 versus 4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. A somewhat lower rate of metastatic infection (9 percent) was noted in a series of 290 patients with KLA from Korea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The findings have been more variable in studies in the United States. There were no cases of metastatic infection among the 23 patients with KLA in a study from New York [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/18\">",
"     18",
"    </a>",
"    ], whereas a review of 18 cases in the United States prior to the New York study found metastatic infection in five (28 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, metastatic infection appears to be a rare complication (2 percent or less) of secondary K. pneumoniae liver abscess, even in Taiwan [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Metastatic infection can also occur with K. pneumoniae infections other than liver abscess. These infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38426?source=see_link&amp;anchor=H6013720#H6013720\">",
"     \"Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection\", section on 'Endophthalmitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38426?source=see_link&amp;anchor=H6013768#H6013768\">",
"     \"Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection\", section on 'Meningitis/brain abscess'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Klebsiella primary liver abscess (KLA) frequently occurs in patients with diabetes but can occur in the absence of underlying predisposing medical conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2269203\">",
"    <span class=\"h2\">",
"     Host factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes mellitus or impaired fasting glucose, present in 70 to 78 percent of patients in three series from Taiwan, is the major observed risk factor for Klebsiella primary liver abscess (KLA) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/3-6,12,13\">",
"     3-6,12,13",
"    </a>",
"    ]. The high prevalence of diabetes or impaired fasting glucose in patients with KLA is not seen with other causes of liver abscess (5 percent with polymicrobial liver abscess and 33 percent with non-K. pneumoniae liver abscess in those series) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism by which diabetes predisposes to KLA is not well understood. One contributory mechanism may be that poor glycemic control impairs neutrophil phagocytosis of K1 and K2 capsular serotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/30\">",
"     30",
"    </a>",
"    ]. However, diabetic patients are also vulnerable to infection caused by",
"    <span class=\"nowrap\">",
"     non-K1/K2",
"    </span>",
"    strains [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21801?source=see_link&amp;anchor=H9#H9\">",
"     \"Microbiology and pathogenesis of Klebsiella pneumoniae infection\", section on 'Primary liver abscess'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fatty liver disease has also been more highly associated with KLA compared with liver abscesses due to other organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although no studies have identified specific human genes that predispose to KLA, the prevalence in Asian patients has raised the possibility that host genetic factors play a role. As an example, Chinese ethnicity itself might be a major factor predisposing to intestinal colonization by serotype",
"    <span class=\"nowrap\">",
"     K1/K2",
"    </span>",
"    K. pneumoniae isolates, which is associated with KLA. In one study that evaluated K. pneumoniae isolates from the stools of healthy adult Chinese residents of Taiwan, Japan, Hong Kong, China, Thailand, Malaysia, Singapore, and Vietnam, 10 percent of the isolates were serotypes",
"    <span class=\"nowrap\">",
"     K1/K2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21801?source=see_link&amp;anchor=H3#H3\">",
"     \"Microbiology and pathogenesis of Klebsiella pneumoniae infection\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21801?source=see_link&amp;anchor=H9#H9\">",
"     \"Microbiology and pathogenesis of Klebsiella pneumoniae infection\", section on 'Primary liver abscess'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Virulence factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Klebsiella primary liver abscess (KLA) is caused by isolates with an increased number of virulence factors compared with other K. pneumoniae isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/1-3,6,11,24\">",
"     1-3,6,11,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In studies from Taiwan, both the K1 capsular serotype and the hypermucoviscosity phenotype are more common in community-acquired compared with nosocomial K. pneumoniae infections [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. These virulence factors are also associated with primary liver abscess, and their higher frequency in community-acquired isolates could explain why isolates from primary liver abscess are almost exclusively acquired in the community [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/1-3,6,11,24\">",
"     1-3,6,11,24",
"    </a>",
"    ]. In a report from Taiwan of 95 K. pneumoniae isolates from secondary bacteremia with an identified source of infection, abscess formation in the liver and other sites was much more common with community-acquired than nosocomial isolates (46 versus 4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The regional distribution of K. pneumoniae virulence factors also appears to play a significant role in the geographic restriction of KLA. In a review of 455 consecutive cases of K. pneumoniae bacteremia in seven countries (Taiwan, South Africa, United States, Australia, Belgium, Turkey, and Argentina), the invasive community-acquired syndrome of liver abscess, meningitis, or endophthalmitis was only seen in Taiwan and South Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/24\">",
"     24",
"    </a>",
"    ]. The isolates from Taiwan and South Africa compared with the other countries were much more likely to have a mucoid phenotype (100 versus 2 percent) and to be rmpA-positive (86 versus 7 percent). Other virulence factors, such as K1 capsular serotype, were common in Taiwan and South Africa but rarely seen in the other countries.",
"   </p>",
"   <p>",
"    The role of virulence factors in KLA is discussed in further detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21801?source=see_link&amp;anchor=H3#H3\">",
"     \"Microbiology and pathogenesis of Klebsiella pneumoniae infection\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21801?source=see_link&amp;anchor=H9#H9\">",
"     \"Microbiology and pathogenesis of Klebsiella pneumoniae infection\", section on 'Primary liver abscess'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1778195\">",
"    <span class=\"h2\">",
"     Risk factors for metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Existing published data are conflicting as to whether diabetes is an independent risk factor for metastatic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/1,3,6,12,34\">",
"     1,3,6,12,34",
"    </a>",
"    ]. Virulence factors of the isolate have been more clearly associated with the development of metastatic disease.",
"   </p>",
"   <p>",
"    The presence of the more virulent K1 serotype is a risk factor for metastatic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. In a report from Taiwan of patients with primary Klebsiella liver abscess (KLA), septic endophthalmitis was present in infections with 12 of 85 K1 strains, 2 of 19 K2 strains, and none of 28",
"    <span class=\"nowrap\">",
"     non-K1/K2",
"    </span>",
"    strains [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/6\">",
"     6",
"    </a>",
"    ]. A similar relationship was seen in the four patients with other sites of metastatic infection: none occurred in the",
"    <span class=\"nowrap\">",
"     non-K1/K2",
"    </span>",
"    strains. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21801?source=see_link&amp;anchor=H4#H4\">",
"     \"Microbiology and pathogenesis of Klebsiella pneumoniae infection\", section on 'Capsular serotypes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Presence of the magA gene is another risk factor for metastatic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/8\">",
"     8",
"    </a>",
"    ]. Among magA-positive isolates, those that also have the kfu iron-uptake system may be particularly associated with metastatic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/35\">",
"     35",
"    </a>",
"    ]. The rmpA gene also appears to be a significant predictor of metastatic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21801?source=see_link&amp;anchor=H11#H11\">",
"     \"Microbiology and pathogenesis of Klebsiella pneumoniae infection\", section on 'Siderophores'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presenting symptoms and signs of K. pneumoniae liver abscess (KLA) are similar to those caused by other etiologies of pyogenic liver abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/3,4,37\">",
"     3,4,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=see_link&amp;anchor=H5#H5\">",
"     \"Pyogenic liver abscess\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a review of 160 cases from Taiwan, the most common clinical features and their frequencies are listed below [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever (93 percent)",
"     </li>",
"     <li>",
"      Right upper quadrant tenderness (71 percent)",
"     </li>",
"     <li>",
"      Nausea, vomiting, diarrhea, or abdominal pain (38 percent)",
"     </li>",
"     <li>",
"      Leukocytosis (70 percent)",
"     </li>",
"     <li>",
"      Elevations in serum alanine and aspartate aminotransferases (59 and 68 percent)",
"     </li>",
"     <li>",
"      Elevations in alkaline phosphatase (78 percent)",
"     </li>",
"     <li>",
"      Elevations in bilirubin (26 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to liver abscesses caused by other organisms, those due to K. pneumoniae are more likely to be solitary and more likely to be monomicrobial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In a report from Taiwan, for example, 65 of 68 were monomicrobial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain imaging findings have been reported more commonly with KLA compared with liver abscesses of other bacterial etiology. On ultrasonography, KLA often have a predominantly solid appearance and, compared with other causes of bacterial liver abscess, have a much smaller quantity of pus at initial aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/38\">",
"     38",
"    </a>",
"    ]. On CT scan, monomicrobial KLA tends to be single, unilobular, and multiloculated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/39\">",
"     39",
"    </a>",
"    ]. When compared with abscesses caused by other bacteria, KLA is more likely to be solid, thin-walled, without rim enhancement, and associated with thrombophlebitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Metastatic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of patients with primary liver abscess has concurrent evidence of or develops metastatic infection at other sites [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/1,3,4,6,8,10,12,13,19,35,41-45\">",
"     1,3,4,6,8,10,12,13,19,35,41-45",
"    </a>",
"    ]. The most common manifestations of metastatic infection are endophthalmitis, meningitis and brain abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/1,3,12\">",
"     1,3,12",
"    </a>",
"    ]. Other manifestations include lumbar or cervical spondylitis and discitis, septic pulmonary emboli, lung abscess, psoas abscess, splenic abscess, necrotizing fasciitis, neck abscess, and osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/1,3,12,17,46\">",
"     1,3,12,17,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38426?source=see_link&amp;anchor=H6013720#H6013720\">",
"     \"Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection\", section on 'Endophthalmitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38426?source=see_link&amp;anchor=H6013768#H6013768\">",
"     \"Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection\", section on 'Meningitis/brain abscess'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to the diagnosis of pyogenic liver abscesses, the diagnosis of primary liver abscess due to K. pneumoniae (KLA) is made when K. pneumonia is isolated from the abscess aspirate or blood of a patient with imaging findings consistent with a liver abscess in the absence of underlying hepatobiliary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=see_link&amp;anchor=H6#H6\">",
"     \"Pyogenic liver abscess\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ultrasonography and computed tomography (CT) are the imaging methods of choice when liver abscess is part of the differential diagnosis in patients with the above clinical manifestations and laboratory abnormalities (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61510 \" href=\"UTD.htm?0/28/449\">",
"     image 1",
"    </a>",
"    ). Imaging for liver abscess may also be warranted in patients who present with K. pneumoniae bacteremia and have persistent fever despite appropriate antibiotic therapy. Some radiographic findings have been associated with KLA compared with liver abscesses due to other pathogens, but these findings alone are not diagnostic of KLA. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Following radiologic identification of a possible liver abscess, image-guided diagnostic aspiration should be performed to confirm a pyogenic process. Specimens should be sent for Gram stain and both aerobic and anaerobic culture. Blood cultures should be obtained from all patients with known or suspected liver abscess since KLA may be associated with bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/10,11,24\">",
"     10,11,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1778351\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of fever and right upper quadrant abdominal pain includes other hepatobiliary disease, colitis, or pneumonia. This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=see_link&amp;anchor=H6#H6\">",
"     \"Differential diagnosis of abdominal pain in adults\", section on 'Upper abdominal pain syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis of patients presenting with a focal liver lesion is broad and includes both malignant and infectious etiologies. Imaging studies (ultrasound or computed tomography [CT]) can usually differentiate abscess from malignancy. In some instances, however, a multilobulated abscess may mimic the heterogeneity of hepatic tumor (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83712 \" href=\"UTD.htm?3/34/3621\">",
"     image 2",
"    </a>",
"    ). Conversely, necrosis of hepatic tumor can appear similar to a highly suppurative abscess on CT. In these diagnostic difficulties, diffusion-weighted magnetic resonance imaging may be useful to differentiate between hepatic abscess and necrotic liver tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36888?source=see_link\">",
"     \"Approach to the patient with a focal liver lesion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a patient with imaging findings consistent with a liver abscess, many different microbiological etiologies are possible and cannot be distinguished without culture or serological data. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=see_link&amp;anchor=H4#H4\">",
"     \"Pyogenic liver abscess\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2270589\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of primary Klebsiella liver abscess (KLA) involves drainage and systemic antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2270532\">",
"    <span class=\"h2\">",
"     Drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous drainage guided by imaging (either ultrasonography or computed tomography [CT]) is used for both diagnosis and treatment and is preferred over surgical drainage. Percutaneous drainage for treatment is recommended even in patients in whom the diagnosis has been made on the basis of positive blood cultures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=see_link&amp;anchor=H11#H11\">",
"     \"Pyogenic liver abscess\", section on 'Drainage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Antibiotic choice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of KLA requires parenteral antibiotic therapy in addition to drainage. Community-acquired KLA isolates rarely produce extended-spectrum beta-lactamases (ESBL) and remain susceptible to cephalosporins [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/14,49\">",
"     14,49",
"    </a>",
"    ]. Initial therapy for KLA may be administered as outlined for empiric management of pyogenic liver abscess, which generally should include coverage for gram-negative and anaerobic organisms (",
"    <a class=\"graphic graphic_table graphicRef67894 \" href=\"UTD.htm?7/21/7517\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=see_link&amp;anchor=H12#H12\">",
"     \"Pyogenic liver abscess\", section on 'Antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent antibiotic therapy should be tailored to results of antibiotic susceptibility testing. In reports from Taiwan and Korea, antibiotic regimens have included extended spectrum beta-lactams and cephalosporins with or without aminoglycosides [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/1,3,14,19\">",
"     1,3,14,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is disagreement regarding the selection of early or late generation cephalosporins. Many favor use of first generation cephalosporins (with or without an aminoglycoside) given their relatively low cost and apparent efficacy with respect to rates of mortality, metastatic infection, and complications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/36\">",
"     36",
"    </a>",
"    ]. However, others have reported higher metastatic infection rates among patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    compared with those treated with a second or third generation cephalosporin, both with or without an aminoglycoside (37 versus 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In regions where third generation cephalosporins are much more costly than first generation cephalosporins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    with or without an aminoglycoside may be the favored antibiotic regimen. However, third generation cephalosporins are favorable if costs are not prohibitive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in the setting of severe infection.",
"   </p>",
"   <p>",
"    Although aminoglycosides penetrate abscess cavities poorly, in theory they may eradicate bloodstream organisms early in the course of infection, potentially decreasing risk for metastatic complications. However, this benefit is unproven and may be outweighed by the toxicity of aminoglycosides. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/34/24104?source=see_link\">",
"     \"Aminoglycosides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2270634\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most cases, antibiotic therapy should be administered for four to six weeks. Longer courses of treatment may be warranted for patients requiring subsequent drainage procedures or with persistent radiographic evidence of abscess. Parenteral antibiotics may be administered for the first two to three weeks until the patient has improved systemically and drainage is complete; the remainder of the course can be completed with oral agents.",
"   </p>",
"   <p>",
"    Follow-up imaging should be used to monitor the response to therapy, to determine the duration of antibiotics, and to assess the need for further aspiration. In general, treatment should be continued until CT imaging demonstrates complete or near complete resolution of the abscess cavity. Some abscesses with a thick capsule may leave a CT abnormality remaining after the infection has been eradicated, and other clinical findings, such as normalization of inflammatory markers, sterile cultures, and the finding of a clear cavity without debris or other content on imaging, can be helpful to distinguish this from persistent infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2270704\">",
"    <span class=\"h2\">",
"     Treatment of metastatic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to systemic antibiotics, local therapy or debridement may be required in patients with metastatic infection. As an example, patients with Klebsiella endophthalmitis should receive intravitreal antibiotics and vitrectomy. Management of the metastatic complications is discussed further in the topic reviews on those clinical syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of K. pneumoniae liver abscess (KLA) is good overall, but the metastatic complications can cause significant morbidity. The largest published experience comes from Taiwan:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 160 cases of KLA (all but one were primary), the mortality rate was 11 percent and relapse occurred in 4.4 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/3\">",
"       3",
"      </a>",
"      ]. Among the 18 patients who died, the main causes of death were fulminant sepsis in nine (all with inadequate or delayed drainage of the abscess), metastatic infection in four (meningitis in two, brain and lung abscess in one, and necrotizing fasciitis in one), and rupture of the abscess in two. The mortality rate was significantly higher (41 percent) in 22 patients with polymicrobial liver abscess, all but one of whom had a biliary tract stone or intraabdominal malignancy. Sepsis was the only cause of death in these patients.",
"     </li>",
"     <li>",
"      A later study evaluated 248 patients with pyogenic liver abscess (171 due to K. pneumoniae and 77 to other bacteria) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/4\">",
"       4",
"      </a>",
"      ]. The mortality rate was significantly lower in patients with K. pneumoniae infection (4.1 versus 20.8 percent), while the relapse rate was the same in the two groups (6.5 versus 6.4 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the mortality rate is relatively low, the morbidity in patients with metastatic endophthalmitis is often high despite aggressive therapy, as many patients have impaired vision or blindness [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/1,45,51-54\">",
"     1,45,51-54",
"    </a>",
"    ]. In addition, patients with meningitis may have persistent neurologic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/1,55\">",
"     1,55",
"    </a>",
"    ], particularly if they have substantial neurologic impairment prior to the onset of antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=see_link&amp;anchor=H16#H16\">",
"     \"Bacterial endophthalmitis\", section on 'Endogenous bacterial endophthalmitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25930?source=see_link\">",
"     \"Diagnosis and treatment of gram-negative bacillary meningitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of adverse outcomes was illustrated in a report of 23 patients with KLA who had metastatic infection involving the eye or central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/1\">",
"     1",
"    </a>",
"    ]. Sixteen had severe irreversible disability, including loss of vision, quadriplegia, paraparesis, or impaired higher cortical function. Good vision at presentation and early therapy have been associated with a higher likelihood of maintenance of vision [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29176/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38426?source=see_link&amp;anchor=H6013720#H6013720\">",
"     \"Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection\", section on 'Endophthalmitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38426?source=see_link&amp;anchor=H6013768#H6013768\">",
"     \"Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection\", section on 'Meningitis/brain abscess'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10608701\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Klebsiella pneumoniae primary liver abscess (KLA) occurs in the absence of hepatobiliary disease and is almost always monomicrobial. Most cases have been reported from Asia or in patients of Asian origin. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Diabetes mellitus or impaired fasting glucose is the most important host risk factor for primary KLA. (See",
"      <a class=\"local\" href=\"#H2269203\">",
"       'Host factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Klebsiella isolates that cause KLA have an increased number of virulence factors compared with other Klebsiella isolates and appear to be restricted geographically. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Virulence factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to the manifestations typical of pyogenic liver abscess, such as fever, leukocytosis, right upper quadrant tenderness, and elevated liver enzymes, a minority of patients with primary KLA can develop metastatic infections at other sites. The most common sites for metastatic infections are the eye, meninges, and brain. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Imaging should be performed in patients with signs and symptoms of a liver abscess or in patients with Klebsiella pneumonia bacteremia who have persistent fevers despite appropriate antibiotic therapy. Diagnosis of primary KLA is made by detection of a liver abscess on imaging (ultrasound or computed tomography [CT]) followed by aspiration of the lesion for Gram stain and aerobic and anaerobic culture. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of KLA requires parenteral antibiotic therapy in addition to drainage, optimally percutaneous. Antibiotic choice should be based upon the results of antibiotic susceptibility testing. A third-generation cephalosporin is preferable if the isolate is susceptible and cost is not prohibitive. Antibiotics should be given for at least four to six weeks, depending on abscess resolution as determined by imaging findings. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Antibiotic choice'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2270634\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The reported mortality rate has ranged from 4 to 11 percent. Metastatic disease to the eyes or brain can cause significant long-term morbidity. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/1\">",
"      Fang CT, Lai SY, Yi WC, et al. Klebsiella pneumoniae genotype K1: an emerging pathogen that causes septic ocular or central nervous system complications from pyogenic liver abscess. Clin Infect Dis 2007; 45:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/2\">",
"      Yu WL, Ko WC, Cheng KC, et al. Association between rmpA and magA genes and clinical syndromes caused by Klebsiella pneumoniae in Taiwan. Clin Infect Dis 2006; 42:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/3\">",
"      Wang JH, Liu YC, Lee SS, et al. Primary liver abscess due to Klebsiella pneumoniae in Taiwan. Clin Infect Dis 1998; 26:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/4\">",
"      Yang CC, Yen CH, Ho MW, Wang JH. Comparison of pyogenic liver abscess caused by non-Klebsiella pneumoniae and Klebsiella pneumoniae. J Microbiol Immunol Infect 2004; 37:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/5\">",
"      Chan KS, Chen CM, Cheng KC, et al. Pyogenic liver abscess: a retrospective analysis of 107 patients during a 3-year period. Jpn J Infect Dis 2005; 58:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/6\">",
"      Fung CP, Chang FY, Lee SC, et al. A global emerging disease of Klebsiella pneumoniae liver abscess: is serotype K1 an important factor for complicated endophthalmitis? Gut 2002; 50:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/7\">",
"      Yeh KM, Kurup A, Siu LK, et al. Capsular serotype K1 or K2, rather than magA and rmpA, is a major virulence determinant for Klebsiella pneumoniae liver abscess in Singapore and Taiwan. J Clin Microbiol 2007; 45:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/8\">",
"      Fang CT, Chuang YP, Shun CT, et al. A novel virulence gene in Klebsiella pneumoniae strains causing primary liver abscess and septic metastatic complications. J Exp Med 2004; 199:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/9\">",
"      Chuang YP, Fang CT, Lai SY, et al. Genetic determinants of capsular serotype K1 of Klebsiella pneumoniae causing primary pyogenic liver abscess. J Infect Dis 2006; 193:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/10\">",
"      Ko WC, Paterson DL, Sagnimeni AJ, et al. Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerg Infect Dis 2002; 8:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/11\">",
"      Tsay RW, Siu LK, Fung CP, Chang FY. Characteristics of bacteremia between community-acquired and nosocomial Klebsiella pneumoniae infection: risk factor for mortality and the impact of capsular serotypes as a herald for community-acquired infection. Arch Intern Med 2002; 162:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/12\">",
"      Cheng DL, Liu YC, Yen MY, et al. Septic metastatic lesions of pyogenic liver abscess. Their association with Klebsiella pneumoniae bacteremia in diabetic patients. Arch Intern Med 1991; 151:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/13\">",
"      Chung DR, Lee SS, Lee HR, et al. Emerging invasive liver abscess caused by K1 serotype Klebsiella pneumoniae in Korea. J Infect 2007; 54:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/14\">",
"      Kang CI, Kim SH, Bang JW, et al. Community-acquired versus nosocomial Klebsiella pneumoniae bacteremia: clinical features, treatment outcomes, and clinical implication of antimicrobial resistance. J Korean Med Sci 2006; 21:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/15\">",
"      Okano H, Shiraki K, Inoue H, et al. Clinicopathological analysis of liver abscess in Japan. Int J Mol Med 2002; 10:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/16\">",
"      Siu LK, Fung CP, Chang FY, et al. Molecular typing and virulence analysis of serotype K1 Klebsiella pneumoniae strains isolated from liver abscess patients and stool samples from noninfectious subjects in Hong Kong, Singapore, and Taiwan. J Clin Microbiol 2011; 49:3761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/17\">",
"      Nadasy KA, Domiati-Saad R, Tribble MA. Invasive Klebsiella pneumoniae syndrome in North America. Clin Infect Dis 2007; 45:e25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/18\">",
"      Rahimian J, Wilson T, Oram V, Holzman RS. Pyogenic liver abscess: recent trends in etiology and mortality. Clin Infect Dis 2004; 39:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/19\">",
"      Lederman ER, Crum NF. Pyogenic liver abscess with a focus on Klebsiella pneumoniae as a primary pathogen: an emerging disease with unique clinical characteristics. Am J Gastroenterol 2005; 100:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/20\">",
"      Fang FC, Sandler N, Libby SJ. Liver abscess caused by magA+ Klebsiella pneumoniae in North America. J Clin Microbiol 2005; 43:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/21\">",
"      Fierer J, Walls L, Chu P. Recurring Klebsiella pneumoniae pyogenic liver abscesses in a resident of San Diego, California, due to a K1 strain carrying the virulence plasmid. J Clin Microbiol 2011; 49:4371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/22\">",
"      McCabe R, Lambert L, Frazee B. Invasive Klebsiella pneumoniae infections, California, USA. Emerg Infect Dis 2010; 16:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/23\">",
"      Anstey JR, Fazio TN, Gordon DL, et al. Community-acquired Klebsiella pneumoniae liver abscesses - an \"emerging disease\" in Australia. Med J Aust 2010; 193:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/24\">",
"      Yu VL, Hansen DS, Ko WC, et al. Virulence characteristics of Klebsiella and clinical manifestations of K. pneumoniae bloodstream infections. Emerg Infect Dis 2007; 13:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/25\">",
"      Harris PJ, Laczek JT, Polish RD, Fraser SL. Two cases of Klebsiella pneumoniae primary liver abscesses; an emerging clinical entity among diabetics. Hawaii Med J 2005; 64:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/26\">",
"      Braiteh F, Golden MP. Cryptogenic invasive Klebsiella pneumoniae liver abscess syndrome. Int J Infect Dis 2007; 11:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/27\">",
"      Gomez C, Broseta A, Otero JR, et al. Primary pyogenic liver abscess cause by magA+ Klebsiella pneumoniae in Spain. Clin Microbiol Newsl 2007; 29:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/28\">",
"      Karama EM, Willermain F, Janssens X, et al. Endogenous endophthalmitis complicating Klebsiella pneumoniae liver abscess in Europe: case report. Int Ophthalmol 2008; 28:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/29\">",
"      Keynan Y, Karlowsky JA, Walus T, Rubinstein E. Pyogenic liver abscess caused by hypermucoviscous Klebsiella pneumoniae. Scand J Infect Dis 2007; 39:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/30\">",
"      Lin JC, Siu LK, Fung CP, et al. Impaired phagocytosis of capsular serotypes K1 or K2 Klebsiella pneumoniae in type 2 diabetes mellitus patients with poor glycemic control. J Clin Endocrinol Metab 2006; 91:3084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/31\">",
"      Yu WL, Chan KS, Ko WC, et al. Lower prevalence of diabetes mellitus in patients with Klebsiella pneumoniae primary liver abscess caused by isolates of K1/K2 than with non-K1/K2 capsular serotypes. Clin Infect Dis 2007; 45:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/32\">",
"      Li J, Fu Y, Wang JY, et al. Early diagnosis and therapeutic choice of Klebsiella pneumoniae liver abscess. Front Med China 2010; 4:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/33\">",
"      Lin YT, Siu LK, Lin JC, et al. Seroepidemiology of Klebsiella pneumoniae colonizing the intestinal tract of healthy Chinese and overseas Chinese adults in Asian countries. BMC Microbiol 2012; 12:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/34\">",
"      Sheu SJ, Kung YH, Wu TT, et al. Risk factors for endogenous endophthalmitis secondary to klebsiella pneumoniae liver abscess: 20-year experience in Southern Taiwan. Retina 2011; 31:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/35\">",
"      Ma LC, Fang CT, Lee CZ, et al. Genomic heterogeneity in Klebsiella pneumoniae strains is associated with primary pyogenic liver abscess and metastatic infection. J Infect Dis 2005; 192:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/36\">",
"      Lee SS, Chen YS, Tsai HC, et al. Predictors of septic metastatic infection and mortality among patients with Klebsiella pneumoniae liver abscess. Clin Infect Dis 2008; 47:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/37\">",
"      Chan KS, Yu WL, Tsai CL, et al. Pyogenic liver abscess caused by Klebsiella pneumoniae: analysis of the clinical characteristics and outcomes of 84 patients. Chin Med J (Engl) 2007; 120:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/38\">",
"      Hui JY, Yang MK, Cho DH, et al. Pyogenic liver abscesses caused by Klebsiella pneumoniae: US appearance and aspiration findings. Radiology 2007; 242:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/39\">",
"      Alsaif HS, Venkatesh SK, Chan DS, Archuleta S. CT appearance of pyogenic liver abscesses caused by Klebsiella pneumoniae. Radiology 2011; 260:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/40\">",
"      Lee NK, Kim S, Lee JW, et al. CT differentiation of pyogenic liver abscesses caused by Klebsiella pneumoniae vs non-Klebsiella pneumoniae. Br J Radiol 2011; 84:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/41\">",
"      Lee HC, Chuang YC, Yu WL, et al. Clinical implications of hypermucoviscosity phenotype in Klebsiella pneumoniae isolates: association with invasive syndrome in patients with community-acquired bacteraemia. J Intern Med 2006; 259:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/42\">",
"      Kawai T. Hypermucoviscosity: an extremely sticky phenotype of Klebsiella pneumoniae associated with emerging destructive tissue abscess syndrome. Clin Infect Dis 2006; 42:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/43\">",
"      Yu WL, Fung CP, Ko WC, et al. Polymerase chain reaction analysis for detecting capsule serotypes K1 and K2 of Klebsiella pneumoniae causing abscesses of the liver and other sites. J Infect Dis 2007; 195:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/44\">",
"      Chou FF, Kou HK. Endogenous endophthalmitis associated with pyogenic hepatic abscess. J Am Coll Surg 1996; 182:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/45\">",
"      Sheu SJ, Chou LC, Hong MC, et al. Risk factors for endogenous endophthalmitis secondary to Klebsiella pneumoniae liver abscess. Zhonghua Yi Xue Za Zhi (Taipei) 2002; 65:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/46\">",
"      Keynan Y, Rubinstein E. Endogenous endophthalmitis caused by hypermucoviscous Klebsiella pneumoniae: an emerging disease in Southeast Asia and beyond. Curr Infect Dis Rep 2008; 10:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/47\">",
"      Awaya H, Ito K, Honjo K, et al. Differential diagnosis of hepatic tumors with delayed enhancement at gadolinium-enhanced MRI: a pictorial essay. Clin Imaging 1998; 22:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/48\">",
"      Chan JH, Tsui EY, Luk SH, et al. Diffusion-weighted MR imaging of the liver: distinguishing hepatic abscess from cystic or necrotic tumor. Abdom Imaging 2001; 26:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/49\">",
"      Lin TL, Tang SI, Fang CT, et al. Extended-spectrum beta-lactamase genes of Klebsiella pneumoniae strains in Taiwan: recharacterization of shv-27, shv-41, and tem-116. Microb Drug Resist 2006; 12:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/50\">",
"      Cheng HP, Siu LK, Chang FY. Extended-spectrum cephalosporin compared to cefazolin for treatment of Klebsiella pneumoniae-caused liver abscess. Antimicrob Agents Chemother 2003; 47:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/51\">",
"      Chen YJ, Kuo HK, Wu PC, et al. A 10-year comparison of endogenous endophthalmitis outcomes: an east Asian experience with Klebsiella pneumoniae infection. Retina 2004; 24:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/52\">",
"      Tan YM, Chee SP, Soo KC, Chow P. Ocular manifestations and complications of pyogenic liver abscess. World J Surg 2004; 28:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/53\">",
"      Yoon YH, Lee SU, Sohn JH, Lee SE. Result of early vitrectomy for endogenous Klebsiella pneumoniae endophthalmitis. Retina 2003; 23:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/54\">",
"      Ang M, Jap A, Chee SP. Prognostic factors and outcomes in endogenous Klebsiella pneumoniae endophthalmitis. Am J Ophthalmol 2011; 151:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29176/abstract/55\">",
"      Fang CT, Chen YC, Chang SC, et al. Klebsiella pneumoniae meningitis: timing of antimicrobial therapy and prognosis. QJM 2000; 93:45.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3124 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-5115C1355F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_31_29176=[""].join("\n");
var outline_f28_31_29176=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10608701\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2269203\">",
"      Host factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Virulence factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1778195\">",
"      Risk factors for metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Metastatic infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1778351\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2270589\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2270532\">",
"      Drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Antibiotic choice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2270634\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2270704\">",
"      Treatment of metastatic infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10608701\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3124\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3124|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/28/449\" title=\"diagnostic image 1\">",
"      Liver abscess CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/34/3621\" title=\"diagnostic image 2\">",
"      Klebsiella pneumoniae liver abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3124|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/21/7517\" title=\"table 1\">",
"      Empiric therapy gram negatives and anaerobes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/34/24104?source=related_link\">",
"      Aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36888?source=related_link\">",
"      Approach to the patient with a focal liver lesion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=related_link\">",
"      Bacterial endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38426?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25930?source=related_link\">",
"      Diagnosis and treatment of gram-negative bacillary meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21801?source=related_link\">",
"      Microbiology and pathogenesis of Klebsiella pneumoniae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=related_link\">",
"      Pyogenic liver abscess",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_31_29177="Operative management of primary and secondary lymphedema";
var content_f28_31_29177=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Operative management of primary and secondary lymphedema",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/31/29177/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/31/29177/contributors\">",
"     Babak Mehrara, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/31/29177/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/31/29177/contributors\">",
"     Russell S Berman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/31/29177/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/31/29177/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/31/29177/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H186726226\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Operative management of primary and secondary lymphedema is typically reserved for localized primary malformations, failed medical management, or recurrent cellulitis in affected extremities. There is no consensus regarding the role of surgery, the optimal surgical approach, or the timing of an operative procedure for extremity lymphedema.",
"   </p>",
"   <p>",
"    The indications, preoperative evaluation, and operative management of primary and secondary lymphedema will be reviewed here. Other characteristics of lymphedema, including etiology, diagnosis, and clinical manifestations, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link\">",
"     \"Clinical manifestations and diagnosis of lymphedema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link\">",
"     \"Prevention and treatment of lymphedema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1657?source=see_link\">",
"     \"Pathophysiology and etiology of edema in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34375?source=see_link\">",
"     \"Clinical manifestations and diagnosis of edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186726305\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conservative measures, including compressive garments and decongestive therapy, are the initial approach for management of lymphedema, as discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link&amp;anchor=H5#H5\">",
"     \"Prevention and treatment of lymphedema\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The indications for operative management of primary and secondary lymphedema include [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Localized primary lesions (including microcystic and macroscopic lymphatic malformations)",
"     </li>",
"     <li>",
"      Failed conservative management",
"     </li>",
"     <li>",
"      Recurrent cellulitis",
"     </li>",
"     <li>",
"      Leakage of lymph into body cavities, organs, or externally",
"     </li>",
"     <li>",
"      Limitation of function",
"     </li>",
"     <li>",
"      Deformity or disfigurement",
"     </li>",
"     <li>",
"      Pain",
"     </li>",
"     <li>",
"      Diminished quality of life, including emotional and psychosocial distress",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The goals of surgical management of lymphedema are to alleviate pain and discomfort, retain or restore function, reduce the risk of infection, prevent disease progression, improve cosmesis, and limit deformity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/7-18\">",
"     7-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no consensus on the timing of surgery or optimal surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/7,19\">",
"     7,19",
"    </a>",
"    ]. The decision to perform an operative procedure to treat lymphedema should be made on a case-by-case basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186730238\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preoperative evaluation should include confirmation that the etiology of the lymphedema is due to a congenital or obstructive lymphatic process and not to edema related to a chronic condition, such as heart failure, venous obstruction, or protein deficiency. Chronic edema is managed medically by treating the underlying disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link&amp;anchor=H802880404#H802880404\">",
"     \"Clinical manifestations and diagnosis of lymphedema\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following preoperative assessments are performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Assess the degree of lymphedema",
"      </strong>",
"      &mdash; The circumference of the affected extremity is compared to the unaffected limb to document the degree of lymphedema. Measurements are taken at fixed intervals at specific anatomic sites (eg, ankle, mid-calf, knee, mid thigh for lower extremity measurements), although there may be significant inter-examiner variability with this approach [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/20\">",
"       20",
"      </a>",
"      ]. Volumetric measurement using water displacement is the most accurate assessment tool, but is cumbersome to perform, provides variable results when compression garments are used or there are changes in patient activity, and hence, is rarely used [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/21\">",
"       21",
"      </a>",
"      ]. Perometry (optoelectronic), a technique that utilizes infrared light, can estimate cross-sectional measurements at multiple intervals and convert this information into limb volume metrics [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/22\">",
"       22",
"      </a>",
"      ]. The degree of lymphedema at other sites is performed by measuring the affected area. In our practice, we measure limb circumference at two points: above and below a major joint. For example, in assessing upper-extremity lymphedema, the circumference is measured 10 cm above and 5 cm below the olecranon on both the affected and unaffected limb.",
"     </li>",
"     <li>",
"      <strong>",
"       Lymphedema Stage",
"      </strong>",
"      &mdash; Staging of lymphedema is typically performed using the Campisi staging system (",
"      <a class=\"graphic graphic_table graphicRef81911 \" href=\"UTD.htm?31/56/32651\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/23\">",
"       23",
"      </a>",
"      ]. Alternatively, the staging system of the International Society of Lymphology [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/24\">",
"       24",
"      </a>",
"      ] or National Cancer Institute Common Terminology Criteria for Adverse Events [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/25\">",
"       25",
"      </a>",
"      ] can be used. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link&amp;anchor=H20#H20\">",
"       \"Clinical manifestations and diagnosis of lymphedema\", section on 'Staging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Venous duplex ultrasound",
"      </strong>",
"      &mdash; For patients who will undergo a physiologic procedure, venous duplex ultrasound is performed to rule out thrombosis, venous insufficiency,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      valvular incompetence [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186726312\">",
"    <span class=\"h1\">",
"     OPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Operative management of lymphedema is categorized into two general approaches: physiologic techniques and reductive techniques. Physiologic procedures are used for patients with early stage lymphedema prior to deposition of excess fat and extensive tissue fibrosis (eg, Campisi stage II or early stage III) (",
"    <a class=\"graphic graphic_table graphicRef81911 \" href=\"UTD.htm?31/56/32651\">",
"     table 1",
"    </a>",
"    ). In contrast, reductive techniques are indicated when patients present with more advanced lymphedema after fat deposition and tissue fibrosis has occurred (eg, Campisi stage III or IV). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186726319\">",
"    <span class=\"h2\">",
"     Physiological techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic techniques create new channels to increase the capacity of the lymphatic system to transport lymph fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/28\">",
"     28",
"    </a>",
"    ]. The fluids trapped in lymphedematous tissues are drained into other lymphatic basins or into the venous circulation. In general, surgical intervention is feasible as long as tissue changes in the affected limb (eg, fibrosis, fat hypertrophy) are not severe. Patients with more advanced lymphedema have been treated with physiologic techniques, however, the results are mixed, and only limited numbers of patients are available for analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The surgical approaches to accomplish this goal include lymphatic bypass procedures, flap transposition procedures, and lymph node transfers. The lymphatic bypass procedures are the most commonly used of the physiological techniques. These procedures require a high level of technical skill, and performance of these procedures should be reserved for those surgeons who have expertise in microvascular surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4258367\">",
"    <span class=\"h3\">",
"     Lymphatic bypass procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphatic bypass procedures are utilized in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failure of conservative management (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link&amp;anchor=H5#H5\">",
"       \"Prevention and treatment of lymphedema\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recurrent cellulitis or lymphangitis",
"     </li>",
"     <li>",
"      Dissatisfaction with compression garments",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Contraindications to lymphatic bypass procedures include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Extensive tissue fibrosis",
"     </li>",
"     <li>",
"      Late stage lymphedema changes (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link&amp;anchor=H20#H20\">",
"       \"Clinical manifestations and diagnosis of lymphedema\", section on 'Staging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Venous hypertension",
"     </li>",
"     <li>",
"      Recurrent cancer",
"     </li>",
"     <li>",
"      Patient noncompliance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both primary and secondary forms of lymphedema can be effectively treated with this approach, although the efficacy of these procedures in primary lymphedema has been debated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/4,7,29,30\">",
"     4,7,29,30",
"    </a>",
"    ]. The lymphatic bypass procedures are categorized as lymphatic-lymphatic bypass and lymphovenous bypass procedures. Lymphaticovenular bypass procedures are a variation of the lymphovenous approach.",
"   </p>",
"   <p>",
"    The basic principle is that the lymphatic vessels distal to the lymphatic obstruction are anastomosed to healthy lymphatic vessels or veins proximal to the obstruction. For example, when the lymphatics are transected at the level of the axilla, a bypass is created by connecting the distal lymphatic vessels in the upper arm to vessels (veins or lymph) proximal to the axillary obstruction. An alternative technique involves using a vein graft harvested from another anatomic site and used as the conduit between transected lymphatic vessels and a draining regional vein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4258819\">",
"    <span class=\"h4\">",
"     Methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several methods used to perform a bypass procedure. There is no general consensus for the specific type of lymphatic bypass procedure to be performed; these decisions are made based on surgeon preference and experience. To help identify the lymphatic vessels, prior to making an incision,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/26/420?source=see_link\">",
"     isosulfan blue dye",
"    </a>",
"    is injected into the subcutaneous tissue distal to the operative site [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/28\">",
"     28",
"    </a>",
"    ]. The most common approaches are described as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Lymphatic-lymphatic",
"      </strong>",
"      bypass procedures utilize soft tissue resected from an unaffected site that is transferred proximal to a site affected with lymphedema and followed by a direct anastomosis of the lymphatic vessels. For example, soft tissues containing lymphatic vessels can be harvested from the anterior thigh and transferred as a graft to the upper third of the arm where proximal and distal collecting lymphatics are identified and microsurgically anastomosed to the donor lymphatics [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/31-33\">",
"       31-33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Lymphovenous",
"      </strong>",
"      bypass procedures are an alternative to the lymphatic-lymphatic technique [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/19,34,35\">",
"       19,34,35",
"      </a>",
"      ]. A vein interposition graft is used to connect the distal lymphatic vessels with vessels proximal to the obstruction. Proximal vessels used in this technique include lymphatic vessels, adjacent veins, or deeper and larger veins. Multiple lymphatic vessels can be anastomosed to the vein graft.",
"     </li>",
"     <li>",
"      <strong>",
"       Lymphaticovenular",
"      </strong>",
"      procedures are a supermicrosurgical technique used to anastomose distal subdermal lymphatic vessels and adjacent venules less than 0.8 mm in diameter [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/28,29,36\">",
"       28,29,36",
"      </a>",
"      ]. Distal subdermal lymphatics are less affected by lymphedema and are more readily available for a bypass procedure than deeper lymphatic channels. The pressure in the subdermal venules is lower than found in the deeper, larger veins. Hence, there is less venous backflow in the subdermal vessels and, at least in theory, should result in a permanent improvement of lymphedema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4258521\">",
"    <span class=\"h4\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the outcome data for physiologic techniques are from retrospective reviews of lymphatic bypass procedures.",
"   </p>",
"   <p>",
"    The rate of complications following lymphatic bypass procedures is low [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/7,28,29,37\">",
"     7,28,29,37",
"    </a>",
"    ]. Most complications are minor, such as delayed wound healing and lymphatic fistula, and typically improve spontaneously. Postoperative cellulitis is uncommon, most likely due to long-term postoperative antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/29,37\">",
"     29,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lymphatic bypass procedures result in highly-variable responses, ranging from a complete response to none. Most authors report modest improvements in limb volumes (30 to 50 percent decreased), although a few individual patients experienced marked reductions, particularly for the upper extremity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/18,27-30,36,38\">",
"     18,27-30,36,38",
"    </a>",
"    ]. Progression of lymphedema is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/18,29,30\">",
"     18,29,30",
"    </a>",
"    ]. Long-term studies (follow-up &gt;3 years) have shown improvements with bypass procedures are maintained even when the use of a compression garment is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/27,29,36\">",
"     27,29,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following studies illustrate the subjective and objective improvements in limb size and a decreased incidence of cellulitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest retrospective review includes approximately 1800 patients undergoing a microsurgical lymphatic-venous bypass procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/27\">",
"       27",
"      </a>",
"      ]. Subjective improvement was reported in 87 percent, objective improvement in 83 percent, and the mean volume reduction was 67 percent. The incidence of cellulitis was decreased by 87 percent following lymphatic bypass procedures.",
"     </li>",
"     <li>",
"      A prospective study of 20 patients with upper-extremity lymphedema following an axillary dissection underwent lymphaticovenular bypass using a supermicrosurgical approach [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/28\">",
"       28",
"      </a>",
"      ]. An improvement in symptoms was reported by 19 patients and 13 had objective evidence of a reduction of lymphedema. The mean volume reduction was 35 percent of the preoperative value at one year of follow-up. No patient experienced postoperative complications or an exacerbation of the lymphedema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The variability of results among the different studies is likely due to a number of factors including retrospective nature of most studies, differences in assessing volume or circumference, length of follow-up, variable use of postoperative compression garments",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    physical therapy, and the use of non-standardized or non-validated questionnaires for subjective analysis.",
"   </p>",
"   <p>",
"    There has been no standardization of assessing volume of lymphedematous limb, and numerous techniques are reported to approximate volume changes following an operative procedure. Few studies report the use of complimentary techniques (eg, volume measurements and bioimpedance or lymphoscintigraphy) to corroborate measurements. Other caveats include mixed series of patients, either based upon etiology (eg, primary congenital conditions, or secondary lymphedema following nodal resections, trauma, or filariasis); location of lymphedema (eg, upper or lower extremity);",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    variable criteria for patient selection, selection of procedures, timing of intervention, and identification of suitable lymphatic vessels for bypass surgery.",
"   </p>",
"   <p>",
"    Several case reports and small series suggest that lymphatic bypass procedures may be effective in reducing primary and secondary genital lymphedema [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/27,29,30,39,40\">",
"     27,29,30,39,40",
"    </a>",
"    ]. Prospective studies are required to evaluate the efficacy of lymphatic bypass procedures in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4258826\">",
"    <span class=\"h3\">",
"     Other procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following procedures are infrequently performed, but are options in select patients. There are little data for outcomes related to flap transfer and lymph node transfer procedures, and there are no data from randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186726375\">",
"    <span class=\"h4\">",
"     Flap transposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anecdotal reports have shown reduction in lymphedema when transposition flaps (eg, fascia lata musculocutaneous flaps, free muscle transfer flaps, omentum) are used to release extensive contractures or replace tissue loss in lymphedematous limbs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/39,41-45\">",
"     39,41-45",
"    </a>",
"    ]. In one case report, restoration of lymphatic flow through the transplanted tissue was demonstrated using lymphoscintigraphy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/43\">",
"     43",
"    </a>",
"    ]. However, unpredictable outcomes make this procedure an unlikely candidate for an initial surgical approach to treat lymphedema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12521?source=see_link&amp;anchor=H713392245#H713392245\">",
"     \"Principles of grafts and flaps for reconstructive surgery\", section on 'Flap choice'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Outcome data for flap transposition procedures are based upon case reports and small series of patients, demonstrating some decrease in lymphedema in the lower extremities, genitalia, upper extremities, and head and neck after free or pedicled flap transposition [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/39,43,44\">",
"     39,43,44",
"    </a>",
"    ]. Greater omentum, used for transfer of lymphedematous fluid from an edematous upper extremity, provided no effective clearance of fluid from the arm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/45\">",
"     45",
"    </a>",
"    ]. These procedures are rarely performed due to their unpredictable outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186739773\">",
"    <span class=\"h4\">",
"     Lymph node transfer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to flap transfers, lymph node transfers are not commonly performed. Although these procedures may hold some promise, additional studies are required to evaluate their efficacy and to identify patient populations that are most likely to benefit.",
"   </p>",
"   <p>",
"    Lymph node transfer procedures involve harvesting healthy lymph nodes from one nodal basin and transferring them en bloc to the site of obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. The nodes are transferred either as an avascular graft or as a microsurgical tissue transfer where the arterial and venous anastomoses are performed to the recipient site. There is no lymphatic anastomosis with this approach. The recipient site can be the site of the lymph node excision or to a nonanatomic site. The rationale for the transfer to a nonanatomic site is not entirely clear, however, some authors have suggested that a &ldquo;lymphatic pump&rdquo; is created when the lymph nodes are transferred nonanatomically [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/15,46\">",
"     15,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outcome data for lymph node transfer procedures are based upon small series of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/15,46,47\">",
"     15,46,47",
"    </a>",
"    ]. Effective engraftment of nonvascularized transfer of lymph node grafts has not been clearly demonstrated. Harvesting of lymph nodes for transfer may cause lymphedema in the donor extremity.",
"   </p>",
"   <p>",
"    A retrospective review of 13 patients with upper-extremity lymphedema following a mastectomy treated with a vascularized groin lymph node transfer to the dorsal surface of the wrist reported a 50 percent mean reduction rate in postoperative lymphedema at 56 months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/46\">",
"     46",
"    </a>",
"    ]. Another approach for lymphedematous upper extremities involves harvesting femoral nodes and transplanting them to the axilla using microsurgical techniques. In a review of 24 women with upper-extremity lymphedema for at least five years, the limb returned to normal size in 10 women and was reduced in 12 women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186726382\">",
"    <span class=\"h2\">",
"     Reductive techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reductive techniques (also called ablative techniques) remove fibrofatty tissue that has been generated from sustained lymphatic fluid stasis. The reductive procedures are designed to reduce bulk due to lymphedema and are palliative, not curative, for patients with secondary lymphedema, but can be curative in patients with localized primary lymphatic malformations. This category of procedures includes direct excision and liposuction. The goals of these techniques are the same as the physiologic techniques: alleviate pain, restore function, reduce swelling, and limit deformity. There are no randomized trials to determine the optimal procedure to treat lymphedema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186726389\">",
"    <span class=\"h3\">",
"     Direct excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of surgical procedures were developed for direct excision of excess tissue, including the skin and subcutaneous tissue, resulting from lymphedema. These procedures are largely of historical significance but can be used in cases of severe primary lymphedema of the genitalia, localized primary lymphedema, and lymphostatic elephantiasis (",
"    <a class=\"graphic graphic_table graphicRef81911 \" href=\"UTD.htm?31/56/32651\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Direct excision can be used to treat lymphedema from primary and secondary etiologies. This technique is used for management of localized primary lymphatic malformations and lymphedema of the extremities and genitalia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1061204\">",
"    <span class=\"h4\">",
"     Localized primary lymphatic malformations",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the skin and subcutaneous tissues are the most common sites to be affected by lymphedema, localized primary lymphatic malformations can affect the axillary nodal basins, retroperitoneum, muscles, bones, and intra-abdominal and intra-thoracic organs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/48\">",
"     48",
"    </a>",
"    ]. The localized lymphatic malformations can be composed of macrocystic, microcystic, or a combination of both types of lesions.",
"   </p>",
"   <p>",
"    There are many small series and case reports on the surgical management of lymphatic malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/17,49-55\">",
"     17,49-55",
"    </a>",
"    ], however, there are no randomized trials assessing the optimal procedure or approach, largely related to the rarity of this congenital abnormality. Surgical management is based upon the location, extent, and composition of the lesion and is the only method that can offer a potential cure for the better-defined macrocystic localized lesions. Lesions that are more diffuse and comprised of predominantly microcystic components are difficult to treat by any ablative procedure, including surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sclerotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most surgical procedures are staged in order to preserve organ and neurovascular function. Preoperative use of sclerotherapy to shrink large lesions should be used judiciously as the resultant scarring can obliterate anatomical planes and increase the risk of injury to vital structures. &nbsp;",
"   </p>",
"   <p>",
"    In addition to a mandatory thorough knowledge of the anatomy, the following general principles are helpful when resecting lymphatic malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Focus on one defined anatomic region at a time",
"     </li>",
"     <li>",
"      Resect as much of the lesion as possible, including neurovascular dissections, without injuring adjacent vital structures",
"     </li>",
"     <li>",
"      Use of nerve stimulators may be helpful in identifying critical nerves",
"     </li>",
"     <li>",
"      Limit the extent of resection to avoid blood loss that exceeds the patient&rsquo;s blood volume",
"     </li>",
"     <li>",
"      Use prolonged closed suction drainage of the resultant cavity from the resected lesion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H447662234\">",
"    <span class=\"h4\">",
"     Extremities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly used excisional procedures for lymphedema limb reduction include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Homans",
"      </strong>",
"      &mdash; The Homans reduction procedure includes debulking the subcutaneous lymphedematous tissues and reconstruction with tissue flaps. A modification of this procedure, total superficial lymphangiectomy, is a two-staged reductive procedure where the skin and the subcutaneous tissue from the medial aspect is resected first followed by a resection of the lateral tissue at a later date [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/14,56\">",
"       14,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Charles",
"      </strong>",
"      &mdash; The Charles reduction procedure includes an en bloc resection of the lymphedematous skin and soft tissue and deep fascia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/57\">",
"       57",
"      </a>",
"      ]. The operative site is covered with split thickness skin grafts, taken either from the resected skin or an unaffected site [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/14,58\">",
"       14,58",
"      </a>",
"      ]. The skin grafts can be applied immediately after resection or delayed [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/59,60\">",
"       59,60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Sistrunk and Thompson",
"      </strong>",
"      &mdash; Sistrunk and later Thompson applied similar techniques for the treatment of upper-extremity lymphedema resulting from breast cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/26,61-63\">",
"       26,61-63",
"      </a>",
"      ]. In these procedures, an elliptical skin and soft tissue excision of the upper extremity is performed in the medial aspect of the arm, and dermal flaps linking the skin and underlying fascia are created in an attempt to foster drainage of superficial lymph channels by the deep collecting system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H447662241\">",
"    <span class=\"h4\">",
"     Genitalia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The operative procedures used to treat lymphedema of male and female genitalia include total excision of the lymphedematous subcutaneous tissue and coverage with local skin flaps or skin grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/64-68\">",
"     64-68",
"    </a>",
"    ]. Recurrence of lymphedema requires further re-excision and reconstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186726396\">",
"    <span class=\"h3\">",
"     Liposuction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of liposuction for lower-extremity lymphedema has not been clearly established [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/69-72\">",
"     69-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lymphedema of the upper arm following breast cancer surgery is associated with a 73 percent increase in adipose tissue by volumetrics; hence, liposuction is an alternative procedure for treating upper-extremity lymphedema [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/73\">",
"     73",
"    </a>",
"    ]. Liposuction should be used in conjunction with compression garments [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/69,74-77\">",
"     69,74-77",
"    </a>",
"    ] and physiologic techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/78\">",
"     78",
"    </a>",
"    ] to treat lymphedema of the upper extremities.",
"   </p>",
"   <p>",
"    The indications for liposuction for the treatment of upper-extremity lymphedema include [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/43,75\">",
"     43,75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Non-pitting edema that has failed conservative management for greater than three months",
"     </li>",
"     <li>",
"      Arm volume differences of at least 600 cc",
"     </li>",
"     <li>",
"      Symptomatic complaints including heaviness, shoulder",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neck strain or pain",
"     </li>",
"     <li>",
"      Functional impairments",
"     </li>",
"     <li>",
"      Recurrent infections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The contraindications for liposuction for the treatment of upper-extremity lymphedema include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lymphangiosarcoma of the affected arm",
"     </li>",
"     <li>",
"      Open wounds in the lymphedematous arm",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H447662757\">",
"    <span class=\"h3\">",
"     Outcomes for reductive techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the outcome data for reductive techniques are from retrospective reviews and small case series and case reports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H663078349\">",
"    <span class=\"h4\">",
"     Direct excision outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Procedures that involve direct excision of lymphedematous tissues are invasive and may result in pain, wound healing complications, infections, lymphatic fistulas, and a mediocre cosmetic result [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/14\">",
"     14",
"    </a>",
"    ]. Severe wound healing complications may, in some cases, even worsen lymphedema necessitating amputation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/79\">",
"     79",
"    </a>",
"    ]. The range and rate of complications is not well reported.",
"   </p>",
"   <p>",
"    The effectiveness of operative management of lymphedema by reductive techniques varies with location and extensiveness of the involved tissues.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Primary lymphedema of extremities and genitalia",
"      </strong>",
"      &mdash; Postoperative complications following surgical excision and reconstruction of the extremities include infection, necrosis of the skin graft, poor cosmesis and poor functional results, and foot edema [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/14\">",
"       14",
"      </a>",
"      ]. Complications following surgical excision of lymphedematous tissue and reconstruction of the genitalia include hemorrhage, urethral injury, infection, painful erection, sexual dysfunction, decreased sensation, and scar in suture line [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/64,65\">",
"       64,65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The largest single institution observational study of excision and reconstructive procedures to reduce the bulk of lymphedematous extremity and genital tissue illustrates the effectiveness of this procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/10\">",
"     10",
"    </a>",
"    ]. Quality of life was assessed using the SF-36 questionnaire.",
"   </p>",
"   <p>",
"    For patients with primary lymphedema of the extremities:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the retrospective component of this study, 78 patients had undergone 174 procedures, and 63 percent (49 patients) noted a decrease in limb size. Of these 49 patients, 71 percent would have opted again for the surgery while only 17 percent (5 of 29 with no improvement) would opt for an attempt at a surgical reduction again. Overall, quality of life improved for 23 patients and physical activity improved for 26.",
"     </li>",
"     <li>",
"      The prospective component included 10 patients; nine reported a decrease in limb size. Seven of the 10 patients would opt for the reconstructive procedure again. Quality of life improved in seven patients and physical activity improved for four.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with primary lymphedema of the genitalia:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the retrospective review of 13 patients (12 male and 1 female) undergoing 32 excision and reconstructive procedures, the overall results were mixed. Quality of life was improved in eight patients, sexual function improved in five, physical activity improved in seven, and 11 stated they would still opt for the surgical attempt to reduce lymphedema. All patients did have a reduction in the size of the genitalia.",
"     </li>",
"     <li>",
"      The prospective review included eight patients, all with reduction in size of the genitalia. Quality of life was improved for seven patients, physical activity was improved for six, sexual function was improved for four, and all eight patients would opt again for surgical excision and reconstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The perception that the operative procedure was worthwhile for reduction of lymphedematous tissue of the extremities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    genitalia was significantly higher in the patients evaluated prospectively compared with patients evaluated retrospectively (83 versus 56 percent). The difference in perception may be secondary to poor recall or a deteriorating quality of life with time. Quality of life was significantly improved for patients undergoing genitalia reduction compared with those undergoing surgery for lymphedematous extremities (71 versus 34 percent).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Long term results extremity lymphedema",
"      </strong>",
"      &mdash; A retrospective review of 38 patients with lower-extremity lymphedema (primary or secondary) treated by skin and subcutaneous excision found long lasting decrease in lymphedema and improved function and contour in 30 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/59\">",
"       59",
"      </a>",
"      ]. The average length of follow-up was 14 years (range 3 to 17 years). Five patients had progression of lymphedema following the procedure, and the sixth patient had progression of lymphedema associated with weight gain.",
"     </li>",
"     <li>",
"      <strong>",
"       Localized lesions",
"      </strong>",
"      &mdash; The recurrence rate after macroscopically resecting a localized lesion ranges from 15 to 40 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/48\">",
"       48",
"      </a>",
"      ]. Recurrence is hypothesized to result from a regrowth and re-expansion of microscopic, unresected lymphatic channels. Cutaneous vesicles may occur within the surgical scar and can be managed with additional surgical resections",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sclerotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H663078356\">",
"    <span class=\"h4\">",
"     Liposuction outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, circumferential liposuction for lymphedema is safe with few reported postoperative complications. When complications do occur, they tend to be minor and include occasional paresthesias and minor wound healing issues. The use of tourniquets and tumescent technique significantly decreases blood loss, and patients rarely require transfusions. Liposuction alone provides only temporary and palliative relief of symptoms for mild cases of lymphedema [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cadaver and imaging studies",
"      </strong>",
"      &mdash; Cadaver and imaging studies have demonstrated that liposuction does not disrupt lymphatic vessels (if performed parallel to the limb) and that treatment of lymphedema with liposuction does",
"      <strong>",
"      </strong>",
"      not decrease the already impaired lymphatic transport capacity of the limb [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/69,75,76,80-82\">",
"       69,75,76,80-82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Upper extremity",
"      </strong>",
"      &mdash;The following prospective studies illustrate the results of liposuction for patients with upper arm lymphedema following an axillary dissection for breast cancer:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A review of 37 patients with unilateral non-pitting stage II lymphedema treated with conservative management for two to four days followed by circumferential suction assisted liposuction and continued use of compression therapy found the mean reduction in upper arm volumes was 118 percent 12 months after the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective case matched study (n = 28) found that patients treated with liposuction with continued use of controlled compression therapy had significantly decreased lymphedema compared with patients undergoing controlled compression therapy alone after one year (mean difference = 1000 mL) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Liposuction combined with physiologic techniques (myocutaneous flap transfer and lymph fascia grafting) in 11 patients with severe lymphedema of the upper extremity resulted in an approximate 10 percent decrease in lymphedema after three years [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/78\">",
"       78",
"      </a>",
"      ]. The mean number of episodes of cellulitis decreased after the surgical procedure compared with preoperative episodes (0.7 versus 6.5 episodes per year).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Lower extremity",
"      </strong>",
"      &mdash; Evidence for efficacy of liposuction for lower-extremity lymphedema is less convincing and comprised primarily of case reports and small series [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/39,62,63,69-72,79\">",
"       39,62,63,69-72,79",
"      </a>",
"      ]. The initial reports showed only minor improvements with lower-extremity liposuction [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/72,79\">",
"       72,79",
"      </a>",
"      ]. Small series and case studies have found improved cosmetic and functional results with advanced liposuction devices [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/8,63,71,74,83\">",
"       8,63,71,74,83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186730246\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are admitted for one to five days after surgery for postoperative pain management and wound care [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/18,27,28\">",
"     18,27,28",
"    </a>",
"    ]. The limbs are elevated for 24 hours for more limited procedures and up to one week for more extensive procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/27,28,69\">",
"     27,28,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compression garments are worn postoperatively to prevent the recurrence of lymphedema following physiologic and reductive procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/69\">",
"     69",
"    </a>",
"    ]. The garment fit is reassessed every four to six months to ensure that adequate compression is maintained. There is no consensus on the start time, length of time to continue wearing garments, or even the type of garment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/7,27,28,36\">",
"     7,27,28,36",
"    </a>",
"    ]. Typically, however, compression garments are started one week after surgery and used for 6 to 12 months. Most patients continue to wear garments indefinitely, although in some cases these may be discontinued with close follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/27\">",
"     27",
"    </a>",
"    ]. The use of postoperative compression garments is critical for maintenance of volume reductions in the upper extremity after liposuction. Fluid re-accumulation occurred rapidly without postoperative compression therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/74\">",
"     74",
"    </a>",
"    ]. Compression garments are adjusted as necessary to maintain a tight fit. Data assessing the effectiveness of upper-extremity liposuction is based upon small series of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/74-76\">",
"     74-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibiotics are typically used for one week postoperatively, however, prolonged use of prophylactic antibiotics may extend from four weeks to one year [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/7,18,27\">",
"     7,18,27",
"    </a>",
"    ]. The skin is managed with water-based, gentle moisturizing creams to prevent skin drying or cracking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24856402\">",
"    <span class=\"h1\">",
"     NIH LYMPHEDEMA CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Institute of Health Clinical Trials website lists the actively recruiting trials for the assessment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    management of lymphedema (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00064857\">",
"     file://clinicaltrials.gov/ct2/show/NCT00064857",
"    </a>",
"    ). A variety of approaches are being evaluated, including exercises, laser therapy, liposuction, compression garments, and pulsed electromagnetic fields among other interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186726410\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS AND EXPERIMENTAL PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because secondary lymphedema results in functional impairment and poor cosmesis, attempts have been made to prevent the occurrence using physiologic procedures at the time of a lymphadenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/26,28,34,37,61,84\">",
"     26,28,34,37,61,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective trial included 46 patients with breast cancer undergoing an axillary lymphadenectomy with or without a lymphaticovenous anastomosis (lymphatic vessels anastomosed to branches of the axillary vein) performed at the same operative setting. Patients treated with a lymphaticovenous anastomosis (lymphatic vessels anastomosed to branches of the axillary vein) had a lower risk of lymphedema compared with patients without the procedure at 18 months of follow-up (4 versus 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29177/abstract/61\">",
"     61",
"    </a>",
"    ]. The definition of lymphedema was 100 mL volume displacement in this trial whereas others used 200 mL as the definition of lymphedema. This discrepancy in definition of lymphedema should be standardized for ease in evaluating various treatment and preventive approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186726425\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of primary and secondary lymphedema is typically nonsurgical. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link\">",
"     \"Prevention and treatment of lymphedema\"",
"    </a>",
"    .) The decision to perform an operative procedure to treat lymphedema should be made on a case-by-case basis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Operative management is reserved for special settings, such as failed medical management or recurrent cellulitis. There is no consensus for the optimal surgical intervention or timing of a procedure. (See",
"      <a class=\"local\" href=\"#H186726305\">",
"       'Indications for surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preoperative evaluation should include confirmation of etiology of the lymphedema (eg, congenital process or obstructive process versus chronic condition such as heart disease), limb measurements or volumetric assessment to determine degree of lymphedema, and in select cases, venous duplex ultrasound to assess for valvular competency",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombosis. (See",
"      <a class=\"local\" href=\"#H186730238\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physiologic procedures create new channels to increase the capacity of the lymphatic system to transport lymph fluid. The basic principle is that the lymphatic vessels distal to the lymphatic obstruction are anastomosed to healthy lymphatic vessels or veins proximal to the obstruction. (See",
"      <a class=\"local\" href=\"#H186726319\">",
"       'Physiological techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reductive techniques (also called ablative techniques) remove fibrofatty tissue that has been generated from sustained lymphatic fluid stasis. (See",
"      <a class=\"local\" href=\"#H186726382\">",
"       'Reductive techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We use physiologic procedures for patients with early-stage lymphedema prior to deposition of excess fat and extensive tissue fibrosis (eg, Campisi stage II or early stage III) (",
"      <a class=\"graphic graphic_table graphicRef81911 \" href=\"UTD.htm?31/56/32651\">",
"       table 1",
"      </a>",
"      ). We use reductive techniques when patients present with more advanced lymphedema after fat deposition and tissue fibrosis has occurred (eg, Campisi stage III or IV). (See",
"      <a class=\"local\" href=\"#H186726312\">",
"       'Operative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Localized primary lymphatic malformations are excised. (See",
"      <a class=\"local\" href=\"#H1061204\">",
"       'Localized primary lymphatic malformations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/1\">",
"      Ahmed RL, Prizment A, Lazovich D, et al. Lymphedema and quality of life in breast cancer survivors: the Iowa Women's Health Study. J Clin Oncol 2008; 26:5689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/2\">",
"      Pyszel A, Malyszczak K, Pyszel K, et al. Disability, psychological distress and quality of life in breast cancer survivors with arm lymphedema. Lymphology 2006; 39:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/3\">",
"      Franks PJ, Moffatt CJ, Doherty DC, et al. Assessment of health-related quality of life in patients with lymphedema of the lower limb. Wound Repair Regen 2006; 14:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/4\">",
"      Beaulac SM, McNair LA, Scott TE, et al. Lymphedema and quality of life in survivors of early-stage breast cancer. Arch Surg 2002; 137:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/5\">",
"      Brady MS, Garfein CF, Petrek JA, Brennan MF. Post-treatment sarcoma in breast cancer patients. Ann Surg Oncol 1994; 1:66.",
"     </a>",
"    </li>",
"    <li>",
"     Smithers CJ, Fishman SJ. Chapter 74: Vascular anomalies.  Lymphatic malformations. In: Ashcraft's Pediatric Surgery, 5th ed, Holcomb GW III, Murphy JP, Ostlie DJ (Eds), Saunders Elsevier, Philadelphia 2010. p.989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/7\">",
"      Demirtas Y, Ozturk N, Yapici O, Topalan M. Comparison of primary and secondary lower-extremity lymphedema treated with supermicrosurgical lymphaticovenous anastomosis and lymphaticovenous implantation. J Reconstr Microsurg 2010; 26:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/8\">",
"      Espinosa-de-Los-Monteros A, Hinojosa CA, Abarca L, Iglesias M. Compression therapy and liposuction of lower legs for bilateral hereditary primary lymphedema praecox. J Vasc Surg 2009; 49:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/9\">",
"      van der Walt JC, Perks TJ, Zeeman BJ, et al. Modified Charles procedure using negative pressure dressings for primary lymphedema: a functional assessment. Ann Plast Surg 2009; 62:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/10\">",
"      Ogunbiyi SO, Modarai B, Smith A, et al. Quality of life after surgical reduction for severe primary lymphoedema of the limbs and genitalia. Br J Surg 2009; 96:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/11\">",
"      Kitsiou-Tzeli S, Vrettou C, Leze E, et al. Milroy's primary congenital lymphedema in a male infant and review of the literature. In Vivo 2010; 24:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/12\">",
"      Lee B, Andrade M, Bergan J, et al. Diagnosis and treatment of primary lymphedema. Consensus document of the International Union of Phlebology (IUP)-2009. Int Angiol 2010; 29:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/13\">",
"      Symvoulakis EK, Anyfantakis DI, Lionis C. Primary lower limb lymphedema: a focus on its functional, social and emotional impact. Int J Med Sci 2010; 7:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/14\">",
"      Tiwari A, Cheng KS, Button M, et al. Differential diagnosis, investigation, and current treatment of lower limb lymphedema. Arch Surg 2003; 138:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/15\">",
"      Suami H, Chang DW. Overview of surgical treatments for breast cancer-related lymphedema. Plast Reconstr Surg 2010; 126:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/16\">",
"      Brennan MJ, Miller LT. Overview of treatment options and review of the current role and use of compression garments, intermittent pumps, and exercise in the management of lymphedema. Cancer 1998; 83:2821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/17\">",
"      Oztun&ccedil; F, Koca B, Adaletli I. Generalised lymphangiomatosis in an 8-year-old girl who presented with cardiomegaly. Cardiol Young 2011; 21:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/18\">",
"      Damstra RJ, Voesten HG, van Schelven WD, van der Lei B. Lymphatic venous anastomosis (LVA) for treatment of secondary arm lymphedema. A prospective study of 11 LVA procedures in 10 patients with breast cancer related lymphedema and a critical review of the literature. Breast Cancer Res Treat 2009; 113:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/19\">",
"      Campisi C, Davini D, Bellini C, et al. Lymphatic microsurgery for the treatment of lymphedema. Microsurgery 2006; 26:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/20\">",
"      Taylor R, Jayasinghe UW, Koelmeyer L, et al. Reliability and validity of arm volume measurements for assessment of lymphedema. Phys Ther 2006; 86:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/21\">",
"      Sander AP, Hajer NM, Hemenway K, Miller AC. Upper-extremity volume measurements in women with lymphedema: a comparison of measurements obtained via water displacement with geometrically determined volume. Phys Ther 2002; 82:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/22\">",
"      Stanton AW, Northfield JW, Holroyd B, et al. Validation of an optoelectronic limb volumeter (Perometer). Lymphology 1997; 30:77.",
"     </a>",
"    </li>",
"    <li>",
"     Campisi C, Campisi C, Accogli S, Campisi C, Boccardo F. Lymphedema staging and surgical indications in geriatric age. BMC Geriatrics 2010; 10(Suppl 1):A50 www.biomedcentral.com (Accessed on May 26, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/24\">",
"      International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema. 2009 Concensus Document of the International Society of Lymphology. Lymphology 2009; 42:51.",
"     </a>",
"    </li>",
"    <li>",
"     National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) available online at file://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (Accessed on April 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/26\">",
"      Boccardo FM, Ansaldi F, Bellini C, et al. Prospective evaluation of a prevention protocol for lymphedema following surgery for breast cancer. Lymphology 2009; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/27\">",
"      Campisi C, Bellini C, Campisi C, et al. Microsurgery for lymphedema: clinical research and long-term results. Microsurgery 2010; 30:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/28\">",
"      Chang DW. Lymphaticovenular bypass for lymphedema management in breast cancer patients: a prospective study. Plast Reconstr Surg 2010; 126:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/29\">",
"      O'Brien BM, Mellow CG, Khazanchi RK, et al. Long-term results after microlymphaticovenous anastomoses for the treatment of obstructive lymphedema. Plast Reconstr Surg 1990; 85:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/30\">",
"      Gloviczki P, Fisher J, Hollier LH, et al. Microsurgical lymphovenous anastomosis for treatment of lymphedema: a critical review. J Vasc Surg 1988; 7:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/31\">",
"      Baumeister RG, Siuda S. Treatment of lymphedemas by microsurgical lymphatic grafting: what is proved? Plast Reconstr Surg 1990; 85:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/32\">",
"      Ho LC, Lai MF, Kennedy PJ. Micro-lymphatic bypass in the treatment of obstructive lymphoedema of the arm: case report of a new technique. Br J Plast Surg 1983; 36:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/33\">",
"      Kleinhans E, Baumeister RG, Hahn D, et al. Evaluation of transport kinetics in lymphoscintigraphy: follow-up study in patients with transplanted lymphatic vessels. Eur J Nucl Med 1985; 10:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/34\">",
"      Campisi C, Boccardo F. Lymphedema and microsurgery. Microsurgery 2002; 22:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/35\">",
"      Campisi C. Use of autologous interposition vein graft in management of lymphedema: preliminary experimental and clinical observations. Lymphology 1991; 24:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/36\">",
"      Koshima I, Inagawa K, Urushibara K, Moriguchi T. Supermicrosurgical lymphaticovenular anastomosis for the treatment of lymphedema in the upper extremities. J Reconstr Microsurg 2000; 16:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/37\">",
"      Demirtas Y, Ozturk N, Yapici O, Topalan M. Supermicrosurgical lymphaticovenular anastomosis and lymphaticovenous implantation for treatment of unilateral lower extremity lymphedema. Microsurgery 2009; 29:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/38\">",
"      Yamamoto Y, Horiuchi K, Sasaki S, et al. Follow-up study of upper limb lymphedema patients treated by microsurgical lymphaticovenous implantation (MLVI) combined with compression therapy. Microsurgery 2003; 23:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/39\">",
"      Chitale VR. Role of tensor fascia lata musculocutaneous flap in lymphedema of the lower extremity and external genitalia. Ann Plast Surg 1989; 23:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/40\">",
"      Mukenge SM, Catena M, Negrini D, et al. Assessment and follow-up of patency after lymphovenous microsurgery for treatment of secondary lymphedema in external male genital organs. Eur Urol 2011; 60:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/41\">",
"      Medgyesi S. A successful operation for lymphoedema using a myocutaneous flap as a \"wick\". Br J Plast Surg 1983; 36:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/42\">",
"      GILLIES H. The lymphatic wick. Proc R Soc Med 1950; 43:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/43\">",
"      Classen DA, Irvine L. Free muscle flap transfer as a lymphatic bridge for upper extremity lymphedema. J Reconstr Microsurg 2005; 21:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/44\">",
"      Withey S, Pracy P, Wood S, Rhys-Evans P. The use of a lymphatic bridge in the management of head and neck lymphoedema. Br J Plast Surg 2001; 54:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/45\">",
"      Goldsmith HS. Long term evaluation of omental transposition for chronic lymphedema. Ann Surg 1974; 180:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/46\">",
"      Lin CH, Ali R, Chen SC, et al. Vascularized groin lymph node transfer using the wrist as a recipient site for management of postmastectomy upper extremity lymphedema. Plast Reconstr Surg 2009; 123:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/47\">",
"      Becker C, Assouad J, Riquet M, Hidden G. Postmastectomy lymphedema: long-term results following microsurgical lymph node transplantation. Ann Surg 2006; 243:313.",
"     </a>",
"    </li>",
"    <li>",
"     Smithers CJ, Fishman SJ. Vascular anomalies. Lymphatic malformations. In: Ashcraft's Pediatric Surgery, 5th, Holcomb GW III, Murphy JP, Ostlie DJ (Eds), Saunders Elsevier, Philadelphia 2010. p.989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/49\">",
"      Ghatak S, Ray S, Sanyal S, et al. An unusual cause of acute abdomen in adults: giant cystic lymphangioma of the pancreatic head. A clinical case and literature review. JOP 2011; 12:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/50\">",
"      Lyngdoh TS, Konsam R, Th B, Marak B. Giant cystic lymphangioma of pancreas. ANZ J Surg 2008; 78:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/51\">",
"      Tsukada H, Takaori K, Ishiguro S, et al. Giant cystic lymphangioma of the small bowel mesentery: report of a case. Surg Today 2002; 32:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/52\">",
"      Chen CW, Hsu SD, Lin CH, et al. Cystic lymphangioma of the jejunal mesentery in an adult: a case report. World J Gastroenterol 2005; 11:5084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/53\">",
"      Karaca G, Ko&ccedil;ak E, Pekici R, et al. A rare cause of acute appendicitis: cystic lymphangioma. Am Surg 2010; 76:E150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/54\">",
"      Tubbs RS, Bradley N, Harmon D, et al. Involvement of the brachial plexus and its branches by cystic hygromas. J Neurosurg Pediatr 2011; 7:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/55\">",
"      Maa J, Wa C, Jaigirdir A, et al. Giant mesenteric cystic lymphangioma presenting with abdominal pain and masquerading as a gynecologic malignancy. Rare Tumors 2009; 1:e48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/56\">",
"      Servelle M. Surgical treatment of lymphedema: a report on 652 cases. Surgery 1987; 101:485.",
"     </a>",
"    </li>",
"    <li>",
"     Charles R. Elephantiasis scroti, Churchill, London 1912.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/58\">",
"      Kinmonth JB, Patrick JH, Chilvers AS. Comments on operations for lower limb lymphoedema. Lymphology 1975; 8:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/59\">",
"      Miller TA, Wyatt LE, Rudkin GH. Staged skin and subcutaneous excision for lymphedema: a favorable report of long-term results. Plast Reconstr Surg 1998; 102:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/60\">",
"      Dumanian GA, Futrell JW. Radical excision and delayed reconstruction of a lymphedematous leg with a 15 year follow-up. Lymphology 1996; 29:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/61\">",
"      Boccardo FM, Casabona F, Friedman D, et al. Surgical prevention of arm lymphedema after breast cancer treatment. Ann Surg Oncol 2011; 18:2500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/62\">",
"      Sistrunk WE. CONTRIBUTION TO PLASTIC SURGERY: REMOVAL OF SCARS BY STAGES; AN OPEN OPERATION FOR EXTENSIVE LACERATION OF THE ANAL SPHINCTER; THE KONDOLEON OPERATION FOR ELEPHANTIASIS. Ann Surg 1927; 85:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/63\">",
"      Thompson N. The surgical treatment of chronic lymphoedema of the extremities. Surg Clin North Am 1967; 47:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/64\">",
"      Ross JH, Kay R, Yetman RJ, Angermeier K. Primary lymphedema of the genitalia in children and adolescents. J Urol 1998; 160:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/65\">",
"      Dandapat MC, Mohapatro SK, Patro SK. Elephantiasis of the penis and scrotum. A review of 350 cases. Am J Surg 1985; 149:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/66\">",
"      Zacharakis E, Dudderidge T, Zacharakis E, Ioannidis E. Surgical repair of idiopathic scrotal elephantiasis. South Med J 2008; 101:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/67\">",
"      Jain VK, Singh S, Garge S, Negi A. Saxophone penis due to primary lymphoedema. J Indian Assoc Pediatr Surg 2009; 14:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/68\">",
"      Garaffa G, Christopher N, Ralph DJ. The management of genital lymphoedema. BJU Int 2008; 102:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/69\">",
"      Brorson H, Ohlin K, Olsson G, et al. Controlled compression and liposuction treatment for lower extremity lymphedema. Lymphology 2008; 41:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/70\">",
"      Eryilmaz T, Kaya B, Ozmen S, Kandal S. Suction-assisted lipectomy for treatment of lower-extremity lymphedema. Aesthetic Plast Surg 2009; 33:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/71\">",
"      Greene AK, Slavin SA, Borud L. Treatment of lower extremity lymphedema with suction-assisted lipectomy. Plast Reconstr Surg 2006; 118:118e.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/72\">",
"      Sando WC, Nahai F. Suction lipectomy in the management of limb lymphedema. Clin Plast Surg 1989; 16:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/73\">",
"      Brorson H, Ohlin K, Olsson G, Karlsson MK. Breast cancer-related chronic arm lymphedema is associated with excess adipose and muscle tissue. Lymphat Res Biol 2009; 7:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/74\">",
"      Brorson H, Svensson H. Liposuction combined with controlled compression therapy reduces arm lymphedema more effectively than controlled compression therapy alone. Plast Reconstr Surg 1998; 102:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/75\">",
"      Brorson H. Liposuction in arm lymphedema treatment. Scand J Surg 2003; 92:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/76\">",
"      Brorson H. Liposuction gives complete reduction of chronic large arm lymphedema after breast cancer. Acta Oncol 2000; 39:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/77\">",
"      Damstra RJ, Voesten HG, Klinkert P, Brorson H. Circumferential suction-assisted lipectomy for lymphoedema after surgery for breast cancer. Br J Surg 2009; 96:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/78\">",
"      Qi F, Gu J, Shi Y, Yang Y. Treatment of upper limb lymphedema with combination of liposuction, myocutaneous flap transfer, and lymph-fascia grafting: a preliminary study. Microsurgery 2009; 29:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/79\">",
"      Miller TA. Charles procedure for lymphedema: a warning. Am J Surg 1980; 139:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/80\">",
"      Hoffmann JN, Fertmann JP, Baumeister RG, et al. Tumescent and dry liposuction of lower extremities: differences in lymph vessel injury. Plast Reconstr Surg 2004; 113:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/81\">",
"      Frick A, Hoffmann JN, Baumeister RG, Putz R. Liposuction technique and lymphatic lesions in lower legs: anatomic study to reduce risks. Plast Reconstr Surg 1999; 103:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/82\">",
"      Brorson H, Svensson H, Norrgren K, Thorsson O. Liposuction reduces arm lymphedema without significantly altering the already impaired lymph transport. Lymphology 1998; 31:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/83\">",
"      O'Brien BM, Khazanchi RK, Kumar PA, et al. Liposuction in the treatment of lymphoedema; a preliminary report. Br J Plast Surg 1989; 42:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29177/abstract/84\">",
"      Boccardo F, Casabona F, De Cian F, et al. Lymphedema microsurgical preventive healing approach: a new technique for primary prevention of arm lymphedema after mastectomy. Ann Surg Oncol 2009; 16:703.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16401 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-A6750C7309-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_31_29177=[""].join("\n");
var outline_f28_31_29177=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H186726425\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H186726226\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H186726305\">",
"      INDICATIONS FOR SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H186730238\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H186726312\">",
"      OPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H186726319\">",
"      Physiological techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4258367\">",
"      - Lymphatic bypass procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4258819\">",
"      Methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4258521\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4258826\">",
"      - Other procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H186726375\">",
"      Flap transposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H186739773\">",
"      Lymph node transfer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H186726382\">",
"      Reductive techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H186726389\">",
"      - Direct excision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1061204\">",
"      Localized primary lymphatic malformations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H447662234\">",
"      Extremities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H447662241\">",
"      Genitalia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H186726396\">",
"      - Liposuction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H447662757\">",
"      - Outcomes for reductive techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H663078349\">",
"      Direct excision outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H663078356\">",
"      Liposuction outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H186730246\">",
"      POSTOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24856402\">",
"      NIH LYMPHEDEMA CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H186726410\">",
"      FUTURE DIRECTIONS AND EXPERIMENTAL PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H186726425\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/16401\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/16401|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/56/32651\" title=\"table 1\">",
"      Campisi staging system for lymphedema",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34375?source=related_link\">",
"      Clinical manifestations and diagnosis of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1657?source=related_link\">",
"      Pathophysiology and etiology of edema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=related_link\">",
"      Prevention and treatment of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12521?source=related_link\">",
"      Principles of grafts and flaps for reconstructive surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_31_29178="Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients";
var content_f28_31_29178=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/31/29178/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/31/29178/contributors\">",
"     John R Wingard, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/31/29178/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/31/29178/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/31/29178/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/31/29178/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/31/29178/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H20422799\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive fungal infections are common in selected hematopoietic cell transplant recipients (HCT), such as allogeneic HCT recipients during the preengraftment period and in those with severe graft-versus-host disease, and cause substantial morbidity and mortality.",
"   </p>",
"   <p>",
"    Interest in antifungal prophylaxis for high-risk HCT recipients has been prompted by the rising incidence of life-threatening invasive fungal infections in such patients, the difficulty in establishing the diagnosis early in the course of infection, and the recognition that treatment outcomes are poor if initiation of therapy is delayed.",
"   </p>",
"   <p>",
"    The epidemiology and prophylaxis of invasive fungal infections in HCT recipients will be discussed here. The epidemiology and prophylaxis of invasive fungal infections in patients with hematologic malignancies is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other important issues related to infections in HCT recipients are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link\">",
"       \"Overview of neutropenic fever syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=see_link\">",
"       \"Diagnostic approach to the adult presenting with neutropenic fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"       \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=see_link\">",
"       \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=see_link\">",
"       \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link\">",
"       \"Treatment of candidemia and invasive candidiasis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"       \"Treatment and prevention of invasive aspergillosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link\">",
"       \"Mucormycosis (zygomycosis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=see_link\">",
"       \"Treatment and prevention of Fusarium infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20422806\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both yeasts and molds cause serious invasive fungal infections in hematopoietic cell transplant (HCT) recipients (",
"    <a class=\"graphic graphic_figure graphicRef52716 \" href=\"UTD.htm?8/10/8362\">",
"     figure 1",
"    </a>",
"    ). Prior to the routine use of antifungal prophylaxis, Candida spp accounted for the majority of fungal infections that occurred during the preengraftment period of HCT, followed by Aspergillus spp. More recently, Aspergillus has surpassed Candida as a cause of invasive fungal infections in HCT recipients, associated with the use of effective antifungal prophylaxis targeting Candida spp [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/1\">",
"     1",
"    </a>",
"    ]. Both pathogens are associated with substantial risk for mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20422813\">",
"    <span class=\"h2\">",
"     Candida infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida is the most important yeast pathogen in HCT recipients, accounting for most invasive yeast infections [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Meta-analyses and randomized trials have determined that the threshold incidence of Candida infection at which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    prophylaxis appears to be efficacious is 6 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Infection rates at or above this threshold are seen primarily during the preengraftment phase in allogeneic HCT recipients receiving myeloablative conditioning regimens and in some autologous HCT recipients who are not given prophylactic hematopoietic growth factors or who are at risk for severe oral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gastrointestinal mucositis (which is a risk factor for candidemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although Candida is ordinarily a harmless colonizer of mucosal surfaces and skin, breeches in skin or mucosal integrity can lead to invasion of deep tissues and hematogenous dissemination. The portal of entry for this commensal organism is thought to be primarily the gastrointestinal tract in this patient population, with translocation occurring as a result of mucosal injury from cytotoxic chemotherapy and total body irradiation given in the pretransplant conditioning regimen.",
"   </p>",
"   <p>",
"    Candidemia is the most frequent clinical manifestation of invasive candidiasis. Candida is also a common fungal cause of central venous catheter infections. Less commonly, Candida causes disseminated candidiasis, including chronic disseminated candidiasis (hepatosplenic candidiasis). HCT recipients are at highest risk for invasive candidiasis during the preengraftment period (",
"    <a class=\"graphic graphic_figure graphicRef52716 \" href=\"UTD.htm?8/10/8362\">",
"     figure 1",
"    </a>",
"    ). Prior to the routine use of antifungal prophylaxis, the rate of invasive Candida infections was approximately 16 to 18 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=see_link\">",
"     \"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10071?source=see_link\">",
"     \"Hepatosplenic candidiasis (chronic disseminated candidiasis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although C. albicans accounts for about one-half of invasive Candida infections, HCT recipients are also at increased risk for infections caused by non-albicans Candida species (eg, C. glabrata, C. tropicalis) compared with other types of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and pathogenesis of candidemia in adults\", section on 'Prevalence of Candida species'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20422820\">",
"    <span class=\"h2\">",
"     Aspergillus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspergillus is the most common mold pathogen, occurring most commonly during the postengraftment period in patients with severe graft-versus-host disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Among allogeneic HCT recipients, the incidence of invasive aspergillosis ranges from 4 to 24 percent, with most studies reporting rates between 11 and 15 percent; in contrast, the incidence of invasive aspergillosis is only 1 to 2 percent among autologous HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usual portal of entry of this airborne organism is inhalation into the sinuses and respiratory tract. The most frequent manifestation of invasive aspergillosis is pneumonia. Pulmonary infiltrates due to Aspergillus typically consist of one or more nodules with or without surrounding ground glass opacities (the halo sign), cavities, air-crescent signs, or focal airspace consolidation. Other manifestations include sinusitis, localized skin ulcers, subcutaneous nodules, cerebral infarction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fulminant disseminated disease.",
"   </p>",
"   <p>",
"    A. fumigatus is the most common Aspergillus species to cause disease, but several other Aspergillus species also cause invasive disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20422827\">",
"    <span class=\"h2\">",
"     Other fungal infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The agents of mucormycosis are the second most common cause of mold infections in HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], but are infrequent overall at most centers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Mucormycosis can cause life-threatening rhino-orbital, pulmonary, cerebral,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disseminated infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link&amp;anchor=H5#H5\">",
"     \"Mucormycosis (zygomycosis)\", section on 'Risk factors'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Fusarium spp and Scedosporium spp have also been reported in HCT recipients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=see_link\">",
"     \"Mycology, pathogenesis, and epidemiology of Fusarium infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41640?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Scedosporium infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although reactivation of endemic fungi (histoplasmosis, blastomycosis, and coccidioidomycosis) is uncommon in HCT recipients, these fungi should also be considered in patients with prolonged glucocorticoid use or other immunosuppression who have lived in or traveled to endemic areas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=see_link\">",
"     \"Pathogenesis and clinical features of pulmonary histoplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/79?source=see_link\">",
"     \"Mycology, pathogenesis, and epidemiology of blastomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20422834\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for invasive fungal infections in hematopoietic cell transplant (HCT) recipients are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20422848\">",
"    <span class=\"h2\">",
"     Allogeneic HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;After allogeneic HCT, there are two periods of elevated risk for invasive mold infection (",
"    <a class=\"graphic graphic_figure graphicRef52716 \" href=\"UTD.htm?8/10/8362\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/13,21,22\">",
"     13,21,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the neutropenic preengraftment phase, and",
"     </li>",
"     <li>",
"      During the early postengraftment period, especially in patients who develop graft-versus-host disease (GVHD) requiring glucocorticoids",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prior to engraftment, most fungal infections are due to Candida spp and the risk for invasive aspergillosis is low, except in patients with prior Aspergillus infections or in patients who have prolonged neutropenia due to delay in or failure of engraftment. Risk factors for invasive candidiasis during the preengraftment period include neutropenia, severe mucositis, and central venous catheter use [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/23\">",
"     23",
"    </a>",
"    ]. Risk factors for aspergillosis before engraftment include prior multiple chemotherapy regimens, iron overload from multiple erythrocyte transfusions, prior history of invasive aspergillosis, failure to engraft after transplantation, and delayed engraftment such as is often seen with umbilical cord blood transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/13,24\">",
"     13,24",
"    </a>",
"    ]. Patients with advanced or refractory acute myelogenous leukemia are at higher risk of invasive mold infections than other leukemia patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link&amp;anchor=H564717639#H564717639\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\", section on 'Acute leukemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After engraftment, the risk for invasive aspergillosis is much greater. Risk factors for Aspergillus infection after engraftment are GVHD and prolonged courses of glucocorticoids at high doses (&gt;1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    or the equivalent dose of another glucocorticoid) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20422855\">",
"    <span class=\"h2\">",
"     Autologous HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk for invasive fungal infections is lower in autologous HCT recipients than allogeneic HCT recipients, but invasive fungal infections do occur in such patients. Risk factors for Candida infections in autologous HCT recipients include intensive conditioning regimens that cause substantial mucosal injury (resulting in oral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gastrointestinal mucositis), as well as prolonged neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/25\">",
"     25",
"    </a>",
"    ]. Autologous HCT recipients at risk for prolonged neutropenia include those who received a suboptimal number of stem cells and those who did not receive myeloid growth factors following transplantation. Autologous HCT recipients are not usually at high risk for invasive aspergillosis or other mold infections, unless they have a prior history of such an infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20422862\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines have been developed by several organizations for the prevention of invasive fungal infections in hematopoietic cell transplant (HCT) recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/7,23,26-28\">",
"     7,23,26-28",
"    </a>",
"    ]. The recommendations below are generally in keeping with the 2009 international guidelines for preventing infectious complications in HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/23\">",
"     23",
"    </a>",
"    ], and the 2010 Infectious Diseases Society of America (IDSA) guidelines for the use of antimicrobial agents in neutropenic patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/7\">",
"     7",
"    </a>",
"    ]. These and other IDSA guidelines can be accessed through the",
"    <a class=\"external\" href=\"file://www.idsociety.org/IDSA_Practice_Guidelines/\">",
"     IDSA&rsquo;s web site",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Some transplant centers have developed their own protocols for antifungal prophylaxis, which depend at least in part upon local rates of resistance, as well as the overall risk of invasive fungal infections based upon which HCT regimens are used. Practices for antifungal prophylaxis vary widely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20422869\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20422877\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary prophylaxis involves the administration of an antimicrobial agent to prevent infection in patients at increased risk who have not previously had the type of infection being targeted. The benefits of primary antifungal prophylaxis have been demonstrated in multiple studies. Much of the emphasis historically has been on the prevention of Candida infections. However, studies of Aspergillus prevention have intensified in recent years.",
"   </p>",
"   <p>",
"    A 2007 meta-analysis that included 64 randomized trials compared systemic antifungal prophylaxis (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ) with a control arm (placebo, no intervention, or a non-systemic antifungal agent such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    ) in cancer patients receiving myelosuppressive chemotherapy (predominantly for acute leukemia) or undergoing hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/3\">",
"     3",
"    </a>",
"    ]. The following findings were observed in HCT recipients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In allogeneic HCT recipients, antifungal prophylaxis reduced all-cause mortality (relative risk [RR] 0.62, 95% CI 0.45-0.85), fungal-related mortality (RR 0.52, 95% CI 0.27-0.99), and the incidence of documented invasive fungal infection (RR 0.33, 95% CI 0.18-0.63).",
"     </li>",
"     <li>",
"      In autologous HCT recipients, patients who received antifungal prophylaxis with low-dose intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      had similar effect estimates as allogeneic HCT patients, but there were only a few studies and sample sizes were small and lacked the power to reach significance. Changes in practices, including a multitude of new conditioning regimens, routine use of myeloid growth factors, and greater numbers of stem cells in peripheral blood grafts means that the risk of fungal infections with current autologous transplant regimens is not clear and the efficacy of antifungal prophylaxis in patients receiving these regimens has not been studied sufficiently. Thus, the applicability of findings in prior studies is uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2012 meta-analysis that included 20 randomized trials compared mold-active prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    prophylaxis in HCT recipients (14 trials) or patients with hematologic malignancy receiving chemotherapy (6 trials) with the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mold-active prophylaxis reduced the number of proven or probable invasive fungal infections compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      prophylaxis (RR 0.71, 95% CI 0.52-0.98).",
"     </li>",
"     <li>",
"      Mold-active prophylaxis reduced the risk of invasive aspergillosis compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      prophylaxis (RR 0.53, 95% CI 0.37-0.75).",
"     </li>",
"     <li>",
"      Mold-active prophylaxis reduced the risk of invasive fungal infection-related mortality compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      prophylaxis (RR 0.67, 95% CI 0.47-0.96).",
"     </li>",
"     <li>",
"      There was no difference in overall mortality between patients who received mold-active prophylaxis and those who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      prophylaxis.",
"     </li>",
"     <li>",
"      Mold-active prophylaxis was associated with an increased risk of adverse events leading to antifungal discontinuation (RR 1.95, 95% CI 1.24-3.07).",
"      <br/>",
"      <br/>",
"      It is important to note that most of the apparent benefit to anti-mold prophylaxis was observed in the non-HCT patients, and most large trials of HCT recipients have not shown a convincing benefit for anti-mold prophylaxis over",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20422884\">",
"    <span class=\"h3\">",
"     Candida infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized placebo-controlled trials have shown that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    reduces the incidence of invasive Candida infections during the preengraftment period following allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In one of these trials, HCT recipients who received fluconazole had a lower risk of invasive fungal infections (3 versus 16 percent) and fungal infection-related mortality (0.6 versus 5.6 percent), but not all-cause mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/8\">",
"     8",
"    </a>",
"    ]. In another trial, HCT recipients who received fluconazole until day 75 following transplantation had a lower risk of invasive fungal infections (7 versus 18 percent), as well as both fungal infection-related mortality (7 versus 13 percent) and all-cause mortality (20 versus 35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/9\">",
"     9",
"    </a>",
"    ]. In a follow-up study in which patients were followed for eight years following HCT, a continued mortality benefit was observed in the patients who received fluconazole (23 versus 45 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/30\">",
"     30",
"    </a>",
"    ]. Fewer patients who received fluconazole died with invasive candidiasis either early (before day 110; 0.7 versus 9 percent) or late (after day 110; 0.8 versus 8 percent).",
"   </p>",
"   <p>",
"    Meta-analyses and randomized trials have determined that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is efficacious in preventing Candida infections in high-risk patients; the incidence at which this can be appreciated is at or above 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Infection rates at or above this threshold are seen primarily in the following groups of HCT recipients during the preengraftment phase [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allogeneic HCT recipients receiving myeloablative conditioning regimens.",
"     </li>",
"     <li>",
"      Some autologous HCT recipients who are not given prophylactic hematopoietic growth factors or who are at risk for severe oral",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gastrointestinal mucositis (which is a risk factor for candidemia). The transplant regimens best known to cause substantial mucosal injury are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      plus either ablative doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      or total body irradiation. There is a growing list of transplant preparative regimens with varying degree of intensity that have been insufficiently studied with respect to their effects on mucosal integrity, and thus the risk of Candida infection is not well characterized in patients receiving these regimens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20422891\">",
"    <span class=\"h4\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    has been studied most rigorously for Candida prophylaxis, other agents have also been evaluated and are considered acceptable alternatives, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/7\">",
"     7",
"    </a>",
"    ]. We also believe that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    is a reasonable option, since it has the same spectrum of activity as micafungin and caspofungin. When Candida prophylaxis is indicated, we favor fluconazole. Fluconazole has the advantage of being available as both oral and intravenous formulations, excellent tolerability, inexpensive generic formulations, and less severe interactions with concomitant medications compared with the extended-spectrum azoles.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    has several important drawbacks, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Its spectrum of activity against Candida spp is narrower than the echinocandins.",
"     </li>",
"     <li>",
"      Breakthrough infections with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      -resistant Candida species, especially C. krusei and C. glabrata, have been reported.",
"     </li>",
"     <li>",
"      It has no activity against Aspergillus or other molds, in comparison to the other acceptable agents, which have at least some activity against Aspergillus spp.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternative agents have the following benefits and drawbacks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Echinocandins",
"      </strong>",
"      &ndash; The echinocandins (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       micafungin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       anidulafungin",
"      </a>",
"      ) have a broader spectrum of activity than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      , with most common Candida species being susceptible, and an excellent safety record. Its drawbacks are its availability only as an intravenous formulation and its high cost. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9338?source=see_link\">",
"       \"Pharmacology of echinocandins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      <strong>",
"      </strong>",
"      &ndash; Itraconazole is available widely as an oral formulation. The IV formulation has been withdrawn in the United States, but remains available in some countries. The oral formulation is poorly tolerated and has variable bioavailability. Another major drawback is its potential interactions with certain chemotherapy agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H22#H22\">",
"       \"Pharmacology of azoles\", section on 'Itraconazole'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H31#H31\">",
"       \"Pharmacology of azoles\", section on 'Drug interactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      &ndash; Voriconazole has both oral and intravenous formulations but has been noted to cause transient visual disturbances (that are not permanent or serious), perhaps more liver toxicity than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      , and some variability in blood levels in allogeneic HCT recipients. A major drawback is its potential interactions with certain chemotherapy agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H16#H16\">",
"       \"Pharmacology of azoles\", section on 'Voriconazole'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H28#H28\">",
"       \"Pharmacology of azoles\", section on 'Voriconazole'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H31#H31\">",
"       \"Pharmacology of azoles\", section on 'Drug interactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       Posaconazole",
"      </a>",
"      &ndash; Posaconazole is available only as an oral formulation. It has been evaluated primarily for its anti-mold utility, but in trials, low rates of Candida infections were noted and posaconazole is therefore an option for anti-yeast prevention [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/31\">",
"       31",
"      </a>",
"      ]. Its major drawbacks include lack of an intravenous formulation and variability of blood levels after oral administration, as well as its potential interactions with certain chemotherapy agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H9#H9\">",
"       \"Pharmacology of azoles\", section on 'Posaconazole'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H17#H17\">",
"       \"Pharmacology of azoles\", section on 'Posaconazole'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H31#H31\">",
"       \"Pharmacology of azoles\", section on 'Drug interactions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20422898\">",
"    <span class=\"h3\">",
"     Aspergillus (and other mold) infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for Aspergillus prophylaxis varies according to the underlying disease and its therapy. Several trials suggest that the risk-benefit ratio favors prophylaxis when the rate of invasive aspergillosis is at least 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. A meta-analysis that compared mold-active prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    prophylaxis is discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20422877\">",
"     'Primary prophylaxis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Aspergillus prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    has been demonstrated to be beneficial in patients with severe graft-versus-host disease (GVHD) following HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20422944\">",
"    <span class=\"h4\">",
"     Allogeneic HCT recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is effective at reducing rates of invasive Candida infection in allogeneic HCT recipients, but it lacks anti-mold activity. Agents with anti-mold activity include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ; all of these agents also have activity against Candida spp. During the preengraftment period, Candida is the fungal pathogen of greatest concern in the majority of patients and fluconazole is therefore adequate for prophylaxis early after HCT in most patients. However, allogeneic HCT recipients are also at some risk for mold infections during the preengraftment period and are at the highest risk during the postengraftment phase in the setting of severe GVHD. The use of antifungal agents with activity against Aspergillus and other molds has been evaluated in various studies of HCT recipients, both during the preengraftment period and later, in patients with severe GVHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H232631507\">",
"    <span class=\"h5\">",
"     Prophylaxis during the preengraftment period",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    prophylaxis have been studied most extensively in allogeneic HCT recipients during the preengraftment period, and compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , appear to modestly reduce the incidence of invasive fungal infections without conferring a mortality benefit. Relevant findings from trials include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      was compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (with both agents being given until day 100 after HCT) in a randomized double-blind trial conducted in 600 allogeneic HCT recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/18\">",
"       18",
"      </a>",
"      ]. Among patients who received voriconazole versus fluconazole, fungal-free survival (the primary endpoint, defined as freedom from an invasive fungal infection or death at 180 days) was similar (78 versus 75 percent). There were trends toward fewer invasive fungal infections (7 versus 11 percent), Aspergillus infections (9 versus 17), and less frequent use of empiric antifungal therapy (24 versus 30 percent) in patients who received voriconazole compared with those who received fluconazole. In a post-hoc analysis of HCT recipients with acute myelogenous leukemia, those who received voriconazole had significantly improved fungal-free survival (78 versus 61 percent) and fewer invasive fungal infections (8.5 versus 21 percent), but no difference in overall survival (81 versus 72 percent) compared with those who received fluconazole.",
"     </li>",
"     <li>",
"      Similar results were observed in a randomized open-label trial comparing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      in 489 patients undergoing allogeneic HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/33\">",
"       33",
"      </a>",
"      ]. In patients who received voriconazole versus itraconazole, there were no differences in the incidence of proven or probable invasive fungal infections (1.3 versus 2.1 percent) or survival to day 180 (82 versus 81 percent). There were fewer interruptions of study drug with voriconazole. Gastrointestinal adverse effects were more common with itraconazole, but there were more adverse visual and hepatic effects with voriconazole.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      has been compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      in randomized trials using the intravenous formulation and the oral suspension [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. One small trial found fewer fungal infections but no survival benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/34\">",
"       34",
"      </a>",
"      ], whereas another trial showed a trend towards inferior survival and was stopped prematurely due to greater toxicity associated with itraconazole and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      compared with fluconazole and cyclophosphamide and considerable intolerance of itraconazole [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link&amp;anchor=H564717713#H564717713\">",
"       \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\", section on 'Drug interactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Low-dose intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate has been evaluated for the prophylaxis of invasive fungal infections in patients undergoing HCT, with conflicting results [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/36\">",
"       36",
"      </a>",
"      ]. The toxicities of amphotericin B deoxycholate make it unsuitable for use after HCT. Several trials have evaluated lipid formulations of amphotericin B, which is less toxic than amphotericin B deoxycholate, but the efficacy results have been mixed [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/37-40\">",
"       37-40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link&amp;anchor=H17#H17\">",
"       \"Pharmacology of amphotericin B\", section on 'Safety and efficacy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       Posaconazole",
"      </a>",
"      has not been studied during the preengraftment period of HCT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H232631515\">",
"    <span class=\"h5\">",
"     Prophylaxis in patients with GVHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    has been evaluated in the postengraftment period in patients with GVHD requiring high-dose glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/32\">",
"     32",
"    </a>",
"    ]. In a randomized double-blind trial, 600 allogeneic HCT patients with GVHD were assigned to posaconazole (200 mg three times daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (400 mg once daily) for prophylaxis of invasive fungal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/32\">",
"     32",
"    </a>",
"    ]. Patients were eligible for the trial if they had grade II to IV acute GVHD or if they had chronic extensive GVHD or if they were being treated with intensive immunosuppressive therapy (&ge;1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    or the equivalent dose of another glucocorticoid; or antithymocyte globulin; or a combination of two or more immunosuppressive agents) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\"",
"    </a>",
"    ). At the end of the 112 day treatment period, posaconazole was associated with a trend towards fewer proven and probable invasive fungal infections (5.3 versus 9.0 percent, odds ratio [OR] 0.56, 95% CI 0.30-1.07) and a significant reduction in proven or probable invasive aspergillosis (2.3 versus 7.0 percent, OR 0.31, 95% CI 0.13-0.75), which accounted for the majority of infections.",
"   </p>",
"   <p>",
"    Although there were no significant differences in the overall incidence of invasive fungal infections between the patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , significantly fewer patients receiving posaconazole developed breakthrough invasive fungal infections (2.4 versus 7.6 percent), particularly invasive aspergillosis (1.0 versus 5.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/32\">",
"     32",
"    </a>",
"    ]. Mortality from invasive fungal infections was also significantly lower in the posaconazole group (1 versus 4 percent). Treatment-related adverse events were similar in both groups. Some patients (7 percent in the posaconazole group; 10 percent in the fluconazole group) had positive galactomannan assays before enrollment into the trial and thus may have had incipient Aspergillus infections. This raises the possibility that some patients were receiving treatment for established infections rather that prophylaxis, and suggests that the putative benefit of posaconazole as prophylaxis is less than suggested in the report.",
"   </p>",
"   <p>",
"    Because of the uncertainty of the benefit of anti-mold prophylaxis in this situation, practices vary considerably from center to center. Some centers give no anti-mold prophylaxis or give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    prophylaxis while maintaining vigilance for Aspergillus infections with laboratory screening (eg, Aspergillus galactomannan antigen, beta-D-glucan)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    early diagnostic tests for patients with suggestive findings (eg, Aspergillus galactomannan antigen, beta-D-glucan, computed tomography [CT] scans). Other centers use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    prophylaxis in all patients with GVHD requiring high-dose glucocorticoid therapy. Still other centers give anti-mold prophylaxis with either voriconazole or posaconazole in patients who require doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    of at least 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (or the equivalent dose of another glucocorticoid) for longer than three weeks, drawing on the observation that it those patients who require prolonged high-dose glucocorticoids who are at greatest risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/22\">",
"     22",
"    </a>",
"    ]. We use voriconazole prophylaxis for patients with GVHD requiring methylprednisolone of at least 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (or the equivalent dose of another glucocorticoid) for longer than three weeks. Patients requiring high doses of glucocorticoids are generally those with grade 2 to 4 GVHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20422951\">",
"    <span class=\"h4\">",
"     Autologous HCT recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous HCT recipients do not require primary prophylaxis against Aspergillus spp and other molds, given the low rate of such infections in these patients. (See",
"    <a class=\"local\" href=\"#H20422820\">",
"     'Aspergillus infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20422958\">",
"    <span class=\"h4\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current data are insufficient to conclusively determine which mold-active drug is optimal for prophylaxis. The choice of the initial antifungal agent may vary based on an institution's experience (ie, epidemiology and susceptibility patterns), risk for specific mold infections (eg, Aspergillus versus the agents of mucormycosis), and patient category (acute myelogenous leukemia [AML] versus HCT). In general, most experts prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    if Aspergillus is the most likely pathogen for which one has concern (eg, prior infection with Aspergillus, epidemiology at that center, patient population). Voriconazole has been studied more extensively after HCT, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    has been studied more extensively in AML patients. Some experts recommend either voriconazole or posaconazole based on the published literature. But, as mentioned above, there are specific strengths and drawbacks to each agent (see",
"    <a class=\"local\" href=\"#H20422891\">",
"     'Choice of agent'",
"    </a>",
"    above). When the decision is made that anti-mold prophylaxis is justified in an HCT recipient, we generally recommend voriconazole.",
"   </p>",
"   <p>",
"    In patients at increased risk for mucormycosis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    should be given since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    has no activity against the agents of mucormycosis. However, it is important to note that at most centers, aspergillosis accounts for the majority of invasive mold infections. As an example, in a multicenter surveillance study of HCT recipients in the United States, 363 invasive mold infections were detected within the first year following HCT; aspergillosis was diagnosed in 66 percent of cases, whereas mucormycosis was diagnosed in 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/1\">",
"     1",
"    </a>",
"    ]. Among HCT recipients, the reported incidence of mucormycosis has ranged from 0.1 to 2 percent, with the highest incidence in patients with GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the potential for serious drug interactions, concomitant administration of extended-spectrum triazole-based (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ) prophylaxis should be avoided in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    or high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . Caution is advised for concomitant use of the extended-spectrum triazoles with chemotherapy drugs metabolized by the liver, especially those metabolized by cytochrome P450 isoenzymes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link&amp;anchor=H564717713#H564717713\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20422965\">",
"    <span class=\"h3\">",
"     Risk-benefit assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although antifungal prophylaxis has been proven to be efficacious in allogeneic HCT recipients, issues surrounding overuse of antifungal agents (eg, resistance, toxicity, and cost) and the relatively low incidence of invasive fungal infections in these patients have tempered enthusiasm for universal prophylaxis. The risk-benefit analysis must include an assessment of the relative level of immunosuppression and comorbidities to identify individuals at increased risk for invasive fungal infections. The level of immunosuppression is higher following allogeneic HCT compared with other settings, such as following consolidation chemotherapy for leukemia. Important comorbidities include older age, the presence or absence of mucositis, poorly controlled diabetes, smoking history, iron overload from transfusions, and recurrent use of antibacterial agents.",
"   </p>",
"   <p>",
"    Factors that support the use of antifungal prophylaxis in high-risk patients include the substantial morbidity and mortality of invasive fungal infections, and the difficulty in obtaining a timely diagnosis due to the limitations of available diagnostic tests [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20422972\">",
"    <span class=\"h3\">",
"     Approach to primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations represent our approach to antifungal prophylaxis in HCT recipients. These recommendations are generally in keeping with the Infectious Diseases Society of America (IDSA) guidelines for the use of antimicrobial agents in neutropenic patients with cancer and international guidelines for preventing infectious complications in HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/7,23\">",
"     7,23",
"    </a>",
"    ]. It should be noted that there is ongoing controversy about the use of antifungal prophylaxis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link&amp;anchor=H69317229#H69317229\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\", section on 'Risk-benefit assessment'",
"    </a>",
"    ). As a result, practices regarding antifungal prophylaxis differ widely at various cancer centers, and our approach may be different from the approach recommended at a specific institution.",
"   </p>",
"   <p>",
"    We favor the following approach to primary antifungal prophylaxis in HCT recipients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For recipients of myeloablative allogeneic HCT who do not have one of the indications for mold prophylaxis discussed below, we recommend prophylaxis against Candida infections during the preengraftment period with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (200 or 400 mg orally once daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link&amp;anchor=H564717552#H564717552\">",
"       \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\", section on 'Candida infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For autologous HCT recipients who receive conditioning regimens that are expected to cause severe mucositis during the preengraftment period (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      plus either ablative doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      or total body irradiation), we suggest prophylaxis against Candida infections with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (200 or 400 mg orally once daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients who undergo myeloablative allogeneic HCT for acute myelogenous leukemia, we suggest anti-mold prophylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/20\">",
"       20",
"      </a>",
"      ]. When mold prophylaxis is indicated in an HCT recipient, we generally favor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (200 mg orally twice daily), but",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      (200 mg orally three times daily) is an appropriate alternative.",
"     </li>",
"     <li>",
"      Given the association between prolonged neutropenia and invasive aspergillosis, we also suggest prophylaxis during the preengraftment period with a mold-active agent in the subset of HCT recipients with a lengthy duration of neutropenia immediately prior to HCT (eg, patients with aplastic anemia) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/7\">",
"       7",
"      </a>",
"      ] and for those who are anticipated to have slow engraftment (&gt;28 days; eg, umbilical cord blood transplant recipients) or who fail to engraft. In such patients, we generally favor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (200 mg orally twice daily), but",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      (200 mg orally three times daily) is an appropriate alternative.",
"     </li>",
"     <li>",
"      Given the potential for serious drug interactions, administration of extended-spectrum triazole-based (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      ) prophylaxis should be delayed until after completion of the transplant conditioning regimen; an echinocandin can be given safely during the conditioning regimen if a gap in antifungal coverage is unadvisable, such as in a patient with prior aspergillosis. Caution is advised for concomitant use of the extended-spectrum triazoles with chemotherapy drugs metabolized by the liver, especially those metabolized by cytochrome P450 isoenzymes. Recommendations about the timing of triazole administration in such patients are discussed below. Interactions between the anti-mold azoles and immunosuppressive drugs are substantial; reductions of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      doses by approximately 50 percent are important and monitoring of levels of these drugs is necessary to avoid toxicity. Coadministration with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      should be avoided due to extreme potentiation of sirolimus levels. (See",
"      <a class=\"local\" href=\"#H20423021\">",
"       'Drug interactions'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For allogeneic HCT recipients with GVHD requiring",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      at a dose of &ge;1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (or the equivalent dose of another glucocorticoid) for longer than three weeks, we recommend anti-mold prophylaxis. We favor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      in such patients, but",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      is an appropriate alternative. The same precautions regarding drug interactions that are discussed above must be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20422993\">",
"    <span class=\"h2\">",
"     Secondary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have a history of a prior invasive fungal infection, especially Aspergillus infection, are at high risk for recurrence of infection following HCT. This has been best studied in patients with prior Aspergillus infection. In the past, prior mold infection was deemed a contraindication for HCT due to the high risk of recurrent infection and death. However, more recently, it has been shown that continued treatment after initial control (so-called secondary prophylaxis) can prevent reactivation of infection in most patients and permit HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with a history of prior invasive aspergillosis undergoing allogeneic or autologous HCT and for patients with a prolonged period of neutropenia immediately prior to HCT, we recommend antifungal prophylaxis with a mold-active agent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/7\">",
"     7",
"    </a>",
"    ]. The choice of agent depends in part upon the need to avoid drug interactions while chemotherapy is being given.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is the first-line agent for Aspergillus spp, and has been best studied as secondary prophylaxis, but mold-active azoles are usually not given concomitantly with certain chemotherapy regimens with hepatically metabolized drugs. Of note, this is not a concern for agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H20422972\">",
"     'Approach to primary prophylaxis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H20423021\">",
"     'Drug interactions'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link&amp;anchor=H564717727#H564717727\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\", section on 'Approach to primary prophylaxis'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    For patients with prior Candida infections, secondary prophylaxis with the agent should be selected based upon the Candida species and which agent was successful in achieving earlier control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20423000\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of antifungal prophylaxis should be individualized based on the patient&rsquo;s clinical status and history of prior fungal infections. The following general principles can be used to help determine the appropriate duration of prophylaxis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In allogeneic HCT recipients who do not have GVHD, prophylaxis against Candida spp is continued either until engraftment or for up to 75 days following transplantation, which in one trial was associated with continued benefit after engraftment [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/7,9,30\">",
"       7,9,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The optimal duration of antifungal prophylaxis in allogeneic HCT recipients with GVHD has not been defined [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/23\">",
"       23",
"      </a>",
"      ]. In such patients, we continue anti-mold prophylaxis until substantial doses of immunosuppressants (especially glucocorticoids) are no longer required. As an example, we suggest stopping once the dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      drops below 20 mg every other day, but the optimal duration has not been formally studied.",
"     </li>",
"     <li>",
"      In patients who have a history of a prior invasive fungal infection who are receiving secondary prophylaxis following HCT, prophylaxis is usually continued until discontinuation of immunosuppressive therapy. In such patients, follow-up imaging (CT scan of the organ involved in prior infection) and fungal markers (eg, Aspergillus galactomannan antigen, beta-D-glucan) are often obtained two to four weeks after antifungal prophylaxis has been discontinued to ensure that reactivation has not occurred.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20423007\">",
"    <span class=\"h1\">",
"     PREEMPTIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to antifungal prophylaxis involves preemptive therapy. This approach involves targeted screening of high-risk patients for markers of colonization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infection in an attempt to prevent invasive infection. Screening involves checking fungal markers, such as the Aspergillus galactomannan antigen and beta-D-glucan, and chest computed tomography (CT) scanning. This approach is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link&amp;anchor=H833586#H833586\">",
"     \"Treatment and prevention of invasive aspergillosis\", section on 'Preemptive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20423014\">",
"    <span class=\"h1\">",
"     BREAKTHROUGH INFECTIONS AND RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Broad use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    prophylaxis has led to increases in Candida species with reduced susceptibility or resistance to fluconazole (eg, C. glabrata, C. krusei) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Cross-resistance to any azole may occur in Candida species, especially C. glabrata [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Thus, prophylaxis should be limited to those patients who are at substantial risk for invasive infection and one should be mindful of the potential for breakthrough Candida infections, especially from C. krusei or C. glabrata. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=see_link\">",
"     \"Epidemiology and pathogenesis of candidemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An increase in mucormycosis has been reported in several retrospective studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    prophylaxis in several centers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/48-50\">",
"     48-50",
"    </a>",
"    ], but in prospective epidemiologic studies and in controlled prophylaxis trials, mucormycosis remains infrequent and no clear-cut association with voriconazole prophylaxis has been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/1,18,33\">",
"     1,18,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link\">",
"     \"Mucormycosis (zygomycosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to note that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    and other echinocandins are not active against Cryptococcus neoformans, Trichosporon, Fusarium, or filamentous molds other than Aspergillus. In addition, some yeasts can demonstrate relative resistance to these drugs (C. parapsilosis, C. rugosa, C. guilliermondii, and non-Candida yeasts). Failure of caspofungin to prevent aspergillosis has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/51\">",
"     51",
"    </a>",
"    ]. Moreover, the clinical efficacy of the echinocandins for endemic fungi (Histoplasma capsulatum, Blastomyces dermatitidis, Coccidioides spp) has not been demonstrated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15210?source=see_link\">",
"     \"Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9321?source=see_link\">",
"     \"Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29912?source=see_link\">",
"     \"Treatment of blastomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26807?source=see_link\">",
"     \"Manifestations and treatment of extrapulmonary coccidioidomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20423021\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many potential drug interactions between antifungal agents and drugs that may be used concomitantly [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/52\">",
"     52",
"    </a>",
"    ]. Specific drug interactions unique to patients with hematologic malignancies and hematopoietic cell transplant (HCT) recipients are mentioned here.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    deoxycholate used in combination with the calcineurin inhibitor class of immunosuppressive drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) used after HCT is associated with a high risk for severe nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/53\">",
"     53",
"    </a>",
"    ]. The risk of nephrotoxicity is much lower with the lipid formulations of amphotericin B.",
"   </p>",
"   <p>",
"    The triazoles are metabolized by the cytochrome P450 isoenzymes and there are multiple potential drug interactions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      has been associated with a harmful interaction with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , resulting in renal and hepatic toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      has a potential negative inotropic effect and should be avoided in patients with prior congestive heart failure and drugs that could be cardiotoxic (eg, anthracyclines or high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Interactions between the anti-mold azoles and immunosuppressive drugs are substantial; reductions of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      doses by approximately 50 percent are important and monitoring of levels of these drugs is necessary to avoid toxicity.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      increases",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      levels by approximately 10-fold [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/55,56\">",
"       55,56",
"      </a>",
"      ], and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      increases sirolimus levels by approximately eightfold [",
"      <a class=\"abstract\" href=\"UTD.htm?28/31/29178/abstract/57\">",
"       57",
"      </a>",
"      ]. The concomitant use of voriconazole or posaconazole with sirolimus is generally avoided. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H34#H34\">",
"       \"Pharmacology of azoles\", section on 'Selected clinical effects'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the potential for serious drug interactions, concomitant administration of extended-spectrum triazole-based (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ) prophylaxis should be avoided in patients receiving high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . Caution is advised for concomitant use of the extended-spectrum triazoles with chemotherapy drugs metabolized by the liver, especially those metabolized by cytochrome P450 isoenzymes.",
"   </p>",
"   <p>",
"    Some examples of important drug interactions between azoles and other drugs are provided in the Tables (",
"    <a class=\"graphic graphic_table graphicRef66477 \" href=\"UTD.htm?8/51/9021\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55886 \" href=\"UTD.htm?3/6/3181\">",
"     table 2",
"    </a>",
"    ). Drug interactions involving azoles are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H31#H31\">",
"     \"Pharmacology of azoles\", section on 'Drug interactions'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     \"Fluconazole: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     \"Voriconazole: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     \"Itraconazole: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     \"Posaconazole: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, specific interactions of azole agents with other medications may be determined using the drug interaction tool (Lexi-Interact Online). This tool can be accessed from the UpToDate online search page or through the individual drug information topics, section on Drug interactions.",
"   </p>",
"   <p>",
"    A discussion of the interactions between antifungal agents and chemotherapy drugs is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link&amp;anchor=H564717713#H564717713\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20423028\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both yeasts and molds cause serious invasive fungal infections in hematopoietic cell transplant (HCT) recipients. Prior to the routine use of antifungal prophylaxis, Candida spp accounted for the majority of fungal infections that occurred during the preengraftment period of HCT, followed by Aspergillus spp. HCT recipients are at highest risk for Candida infections during the preengraftment period (",
"    <a class=\"graphic graphic_figure graphicRef52716 \" href=\"UTD.htm?8/10/8362\">",
"     figure 1",
"    </a>",
"    ). Aspergillus is the most common mold pathogen and the second most common fungal pathogen in HCT recipients, occurring most commonly during the postengraftment period in patients with severe graft-versus-host disease. (See",
"    <a class=\"local\" href=\"#H20422799\">",
"     'Introduction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H20422813\">",
"     'Candida infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following recommendations represent our approach to antifungal prophylaxis. It should be noted that there is ongoing controversy about the use of antifungal prophylaxis. As a result, practices regarding antifungal prophylaxis differ widely at various cancer centers, and our approach may be different from the approach recommended at a specific institution. (See",
"      <a class=\"local\" href=\"#H20422972\">",
"       'Approach to primary prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20422965\">",
"       'Risk-benefit assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although antifungal prophylaxis has been proven to be efficacious in selected HCT recipients, issues surrounding overuse of antifungal agents (eg, resistance, toxicity, and cost) and the relatively low incidence of invasive fungal infections in these patients have tempered enthusiasm for universal prophylaxis. The risk-benefit analysis must include an assessment of the relative level of immunosuppression and comorbidities to identify those individuals at increased risk for invasive fungal infections. (See",
"      <a class=\"local\" href=\"#H20422965\">",
"       'Risk-benefit assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For recipients of myeloablative allogeneic HCT who do not have an indication for mold prophylaxis, we recommend prophylaxis against Candida infections during the preengraftment period with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (200 or 400 mg orally once daily) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20422972\">",
"       'Approach to primary prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For autologous HCT recipients who receive conditioning regimens that are expected to cause severe mucositis during the preengraftment period (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      plus either ablative doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      or total body irradiation), we suggest prophylaxis against Candida infections with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (200 or 400 mg orally once daily) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20422972\">",
"       'Approach to primary prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who undergo myeloablative allogeneic HCT for acute myelogenous leukemia, we suggest anti-mold prophylaxis rather than narrower anti-Candida prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). When mold prophylaxis is indicated in an HCT recipient, we generally favor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (200 mg orally twice daily), but",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      (200 mg orally three times daily) is an appropriate alternative. (See",
"      <a class=\"local\" href=\"#H20422972\">",
"       'Approach to primary prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the subset of HCT recipients with a lengthy duration of neutropenia immediately prior to HCT (eg, patients with aplastic anemia) and for those who are anticipated to have slow engraftment (&gt;28 days; eg, umbilical cord blood transplant recipients) or who fail to engraft, we suggest prophylaxis during the preengraftment period with an agent that has both anti-mold and anti-Candida activity rather than narrower anti-Candida prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In such patients, we generally favor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (200 mg orally twice daily), but",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      (200 mg orally three times daily) is an appropriate alternative. (See",
"      <a class=\"local\" href=\"#H20422972\">",
"       'Approach to primary prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the potential for serious drug interactions, administration of extended-spectrum triazole-based (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      ) prophylaxis should be delayed until after completion of the transplant conditioning regimen; an echinocandin can be given safely during the conditioning regimen if a gap in antifungal coverage is unadvisable, such as in a patient with prior aspergillosis. Caution is advised for concomitant use of the extended-spectrum triazoles with chemotherapy drugs metabolized by the liver, especially those metabolized by cytochrome P450 isoenzymes. Recommendations about the timing of triazole administration in such patients are discussed below. Interactions between the anti-mold azoles and immunosuppressive drugs are substantial; reductions of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      doses by 50 percent are important and monitoring of levels of these drugs is necessary to avoid toxicity. Coadministration with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      should be avoided due to extreme potentiation of sirolimus levels. (See",
"      <a class=\"local\" href=\"#H20422972\">",
"       'Approach to primary prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20423021\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For allogeneic HCT recipients with graft-versus-host disease requiring",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      at a dose of &ge;1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (or the equivalent dose of another glucocorticoid) for longer than three weeks, we recommend anti-mold prophylaxis rather than no antifungal prophylaxis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We favor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (200 mg orally twice daily) in such patients, but",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      (200 mg orally three times daily) is an appropriate alternative. The same precautions regarding drug interactions that are discussed above must be considered. (See",
"      <a class=\"local\" href=\"#H20422972\">",
"       'Approach to primary prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a history of prior invasive aspergillosis undergoing allogeneic or autologous HCT and for patients with a prolonged period of neutropenia immediately prior to HCT, we recommend antifungal prophylaxis with a mold-active agent (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20422993\">",
"       'Secondary prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20423076\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We would like to acknowledge Dr. Richard A Larson who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/1\">",
"      Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/2\">",
"      Hachem R, Hanna H, Kontoyiannis D, et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008; 112:2493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/3\">",
"      Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007; 25:5471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/4\">",
"      Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000; 89:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/5\">",
"      Bow EJ, Laverdi&egrave;re M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002; 94:3230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/6\">",
"      Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/7\">",
"      Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/8\">",
"      Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/9\">",
"      Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/10\">",
"      Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/11\">",
"      Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100:4358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/12\">",
"      Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/13\">",
"      Wingard JR. The changing face of invasive fungal infections in hematopoietic cell transplant recipients. Curr Opin Oncol 2005; 17:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/14\">",
"      Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Hematol Oncol Clin North Am 2011; 25:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/15\">",
"      Wirk B, Wingard JR. Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients. Mycopathologia 2009; 168:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/16\">",
"      Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/17\">",
"      Wingard JR. Zygomycosis: epidemiology and treatment options. Proceedings of Johns Hopkins Advanced Studies in Medicine 2006; 6:S526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/18\">",
"      Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116:5111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/19\">",
"      Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 2011; 17:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/20\">",
"      Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 2003; 16:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/21\">",
"      Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect Dis Clin North Am 2010; 24:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/22\">",
"      Grow WB, Moreb JS, Roque D, et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/23\">",
"      Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/24\">",
"      Wingard JR. Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant 1999; 5:55.",
"     </a>",
"    </li>",
"    <li>",
"     Norkin M, Wingard JR. Invasive fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. In: Stem Cells in Clinic and Research, Gholamrezanezhad A (Ed), InTech, Rijeka 2011. p.657.",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 1.2012. file://www.nccn.org (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/27\">",
"      Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update. Bone Marrow Transplant 2011; 46:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/28\">",
"      Cornely OA, B&ouml;hme A, Buchheidt D, et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2009; 94:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/29\">",
"      Ethier MC, Science M, Beyene J, et al. Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials. Br J Cancer 2012; 106:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/30\">",
"      Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/31\">",
"      Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/32\">",
"      Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/33\">",
"      Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 2011; 155:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/34\">",
"      Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/35\">",
"      Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/36\">",
"      Riley DK, Pavia AT, Beatty PG, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994; 97:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/37\">",
"      Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/38\">",
"      Cordonnier C, Mohty M, Faucher C, et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. Int J Antimicrob Agents 2008; 31:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/39\">",
"      Penack O, Schwartz S, Martus P, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006; 17:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/40\">",
"      Tollemar J, Ringd&eacute;n O, Andersson S, et al. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/41\">",
"      Lanternier F, Sun HY, Ribaud P, et al. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis 2012; 54:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/42\">",
"      Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/43\">",
"      Cordonnier C, Rovira M, Maertens J, et al. Voriconazole as secondary antifungal prophylaxis in stem cell transplant recipients. Haematologica 2011; 96:e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/44\">",
"      Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/45\">",
"      Wingard JR, Merz WG, Rinaldi MG, et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/46\">",
"      Pfaller MA, Messer SA, Boyken L, et al. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004; 42:3142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/47\">",
"      Tsai HF, Bard M, Izumikawa K, et al. Candida glabrata erg1 mutant with increased sensitivity to azoles and to low oxygen tension. Antimicrob Agents Chemother 2004; 48:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/48\">",
"      Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/49\">",
"      Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/50\">",
"      Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/51\">",
"      Madureira A, Bergeron A, Lacroix C, et al. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents 2007; 30:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/52\">",
"      Gubbins PO, Heldenbrand S. Clinically relevant drug interactions of current antifungal agents. Mycoses 2010; 53:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/53\">",
"      Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/54\">",
"      Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/31/29178/abstract/55\">",
"      Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12:552.",
"     </a>",
"    </li>",
"    <li>",
"     Vfend&reg; package insert. Roerig, a Division of Pfizer, Inc. New York, NY, 2008. file://media.pfizer.com/files/products/uspi_vfend.pdf (Accessed on November 12, 2008).",
"    </li>",
"    <li>",
"     Noxafil (posaconazole). Prescribing information. Kenilworth, NJ: Schering, NJ, 2006. file://www.fda.gov/medwatch/SAFETY/2008/May_PI/Noxafil_PI.pdf (Accessed on December 12, 2008).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16534 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-C1C910ED83-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_31_29178=[""].join("\n");
var outline_f28_31_29178=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20423028\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20422799\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20422806\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20422813\">",
"      Candida infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20422820\">",
"      Aspergillus infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20422827\">",
"      Other fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20422834\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20422848\">",
"      Allogeneic HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20422855\">",
"      Autologous HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20422862\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20422869\">",
"      PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20422877\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20422884\">",
"      - Candida infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20422891\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20422898\">",
"      - Aspergillus (and other mold) infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20422944\">",
"      Allogeneic HCT recipients",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H232631507\">",
"      - Prophylaxis during the preengraftment period",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H232631515\">",
"      - Prophylaxis in patients with GVHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20422951\">",
"      Autologous HCT recipients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20422958\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20422965\">",
"      - Risk-benefit assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20422972\">",
"      - Approach to primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20422993\">",
"      Secondary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20423000\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20423007\">",
"      PREEMPTIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20423014\">",
"      BREAKTHROUGH INFECTIONS AND RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20423021\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20423028\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20423076\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/16534\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16534|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/10/8362\" title=\"figure 1\">",
"      Infections after allogeneic HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16534|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/51/9021\" title=\"table 1\">",
"      Significant interactions involving triazoles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/6/3181\" title=\"table 2\">",
"      Major interactions involving triazoles",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=related_link\">",
"      Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9321?source=related_link\">",
"      Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=related_link\">",
"      Diagnostic approach to the adult presenting with neutropenic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41640?source=related_link\">",
"      Epidemiology and clinical manifestations of Scedosporium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=related_link\">",
"      Epidemiology and pathogenesis of candidemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=related_link\">",
"      Fluconazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10071?source=related_link\">",
"      Hepatosplenic candidiasis (chronic disseminated candidiasis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=related_link\">",
"      Itraconazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26807?source=related_link\">",
"      Manifestations and treatment of extrapulmonary coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/79?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of blastomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=related_link\">",
"      Pathogenesis and clinical features of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9338?source=related_link\">",
"      Pharmacology of echinocandins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=related_link\">",
"      Posaconazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=related_link\">",
"      Primary coccidioidal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=related_link\">",
"      Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adults with hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=related_link\">",
"      Treatment and prevention of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29912?source=related_link\">",
"      Treatment of blastomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15210?source=related_link\">",
"      Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=related_link\">",
"      Voriconazole: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_31_29179="Grade of infusion related reactions NCI CTCAE";
var content_f28_31_29179=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Grading of infusion reactions according to the NCI Common Terminology Criteria for Adverse Events v4.0",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        Mild transient reaction; infusion interruption not indicated; intervention not indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        Therapy or infusion interruption indicated but responds promptly to symptomatic treatment (eg, antihistamines, NSAIDs, narcotics, IV fluids); prophylactic medication indicated for less than or equal to 24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        Prolonged (ie, not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td>",
"        Life-threatening consequences; urgent intervention indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NCI: National Cancer Institute; NSAIDs: nonsteroidal anti-inflammatory drugs.",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Common Terminology Criteria for Adverse Events, version 4.0, June 2010, National Institutes of Health, National Cancer Institute, file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_31_29179=[""].join("\n");
var outline_f28_31_29179=null;
var title_f28_31_29180="Appropriate on scene pediatric prehospital interventions";
var content_f28_31_29180=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Appropriate on scene pediatric prehospital interventions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Initiate cardiac monitoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Measure pulse oximetry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Airway and cervical spine immobilization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Open and maintain the airway",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suction the airway to remove secretions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apply cervical collar and back board immobilization for suspected spinal injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer racemic or L-epinephrine for severe inspiratory stridor (eg, severe croup)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Place an advanced airway, if unable to maintain airway by other means",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Breathing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perform&nbsp;bag-mask ventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer beta agonist therapy for reactive airway disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perform needle decompression for tension pneumothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Circulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Control external hemorrhage (eg, penetrating trauma to extremity)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide cardiopulmonary resuscitation if indicated - at least three cycles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perform synchronized cardioversion and defibrillation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain intravenous or intraosseous access if benefit outweighs delay in transport",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer medications indicated for cardiopulmonary arrest - at least one cycle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer IV fluids for shock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer glucose for hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer medications to control seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Splint extremities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perform eye irrigation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer medications (eg, epinephrine, diphenhydramine, and steroids) for allergic or anaphylactic reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer hydroxocobalamin for cyanide poisoning (eg, home fires)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer pain medication",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_31_29180=[""].join("\n");
var outline_f28_31_29180=null;
var title_f28_31_29181="Low protein diet in ESRD";
var content_f28_31_29181=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F71070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F71070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Graph showing effect of protein restriction on progression of advanced chronic kidney disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 232px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Beneficial effect of dietary protein restriction in patients with near end-stage renal disease (mean GFR 14 to 15 mL/min). At 18 months, patients on a low protein diet (right panel) had no significant further reduction in GFR and only 2 of 31 had progressed to maintenance dialysis. In comparison, the GFR fell by more than 50 percent and 9 of 33 required dialysis in the control group.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Ihle, BU, Becker, GJ, Whitworth, JA, et al, N Engl J Med 1989; 321:1773.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_31_29181=[""].join("\n");
var outline_f28_31_29181=null;
var title_f28_31_29182="Sleep effect muscle training";
var content_f28_31_29182=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sleep effects on timing of airway muscle activity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 191px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Moving time average of upper airway muscle and chest wall EMG. During wakefulness (left panel), chest wall activation is slightly preceded by upper airway muscle activation. During obstructed breathing in sleep (right panel), upper airway activation follows chest wall activation, leaving the upper airway vulnerable to collapse.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Hudgel, DW, Harasick, T. J Appl Physiol 1990; 69:443.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_31_29182=[""].join("\n");
var outline_f28_31_29182=null;
var title_f28_31_29183="Hirschsprung dz barium enema";
var content_f28_31_29183=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hirschsprung's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 356px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Barium enema of an infant with Hirschsprung's disease showing the transition zone between the lower aganglionic bowel and the normal colon above.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George D Ferry, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_31_29183=[""].join("\n");
var outline_f28_31_29183=null;
